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Resumo 
As neoplasias malignas têm vindo a afetar um número crescente de crianças, 
adolescentes e homens em idade reprodutiva. O potencial reprodutivo destes pacientes é 
negativamente afetado pelos regimes quimioterápicos adotados, existindo o risco de estes 
virem a sofrer de infertilidade prolongada. O etoposido é um composto quimioterápico 
citotóxico utilizado no tratamento de diversas neoplasias. É um agente semissintético, da 
classe dos inibidores da topoisomerase II, que aumenta o número de complexos de 
clivagem do DNA, provocando quebras permanentes na dupla cadeia. Além de atuar 
diretamente no DNA, este composto poderá causar danos celulares através da indução de 
stress oxidativo. O etoposido afeta a espermatogénese, e a recuperação da fertilidade após 
a exposição a este agente está associada com a dose utilizada e a duração do tratamento, 
sendo assim difícil de prever. Portanto, existe uma forte necessidade de identificar um 
composto capaz de preservar a fertilidade masculina durante a exposição a etoposido, sem 
interferir com a eficácia do tratamento. O N-acetilcisteína (NAC), um percursor da L-
cisteína, possui propriedades antioxidantes e quimioprotetoras. Anteriormente foi 
demonstrado que este composto é seguro para uso clínico e tem vários efeitos protetores 
nas células. Além disso, estudos indicaram que o NAC é capaz de melhorar os parâmetros 
seminais e proteger as células de Sertoli de danos induzidos pelo stress oxidativo. Como 
foi relatado que o NAC possui propriedades citoprotetoras, o presente trabalho teve como 
objetivo avaliar o seu potencial como preservador da qualidade espermática durante a 
exposição dos espermatozoides humanos a etoposido.  
No nosso estudo, espermatozoides humanos foram incubados durante 2 h a 37°C 
com 25 µg/ml de etoposido, 50 µM de NAC ou uma combinação de ambos os compostos. 
Após incubação, procedeu-se à avaliação dos parâmetros seminais, tais como motilidade, 
morfologia e vitalidade, bem como à análise da fragmentação de DNA e condensação da 
cromatina. Foram também medidos os danos oxidativos e avaliado o metabolismo dos 
espermatozoides por espectroscopia de ressonância magnética nuclear de protões (1H-
RMN). Os nossos resultados demonstram que a exposição a curto prazo ao etoposido 
provoca alterações na cromatina e aumenta a fragmentação do DNA dos espermatozoides. 
Além disso, os resultados obtidos mostram que o etoposido não induz danos oxidativos 
nem causa alterações no perfil glicolítico dos espermatozoides. A adição de NAC aos 
espermatozoides expostos a etoposido preserva a condensação da cromatina, e reduz a 
fragmentação do DNA. 
Assim, embora a exposição a etoposido por um curto prazo não afete a vitalidade, 
é capaz de induzir graves alterações na cromatina, e causar danos no DNA dos 
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espermatozoides. Além de estas alterações puderem comprometer a fertilidade masculina, 
são potencialmente transmissíveis à próxima geração. A adição de NAC aos 
espermatozoides expostos a etoposido protege a integridade da cromatina e reduz a 
fragmentação do DNA. Deste modo, o NAC atua como um agente citoprotetor, protegendo 
os espermatozoides dos danos no DNA induzidos pelo etoposido. Contudo, esta exposição 
a curto prazo não induz danos oxidativos nem provoca alterações no perfil glicolítico destas 
células, sugerindo que este quimioterápico afeta diretamente o DNA dos espermatozoides. 
A capacidade do NAC para proteger os espermatozoides humanos dos danos de DNA 
induzidos pelo etoposido pode ser de relevância clínica. A maioria dos pacientes 
submetidos a quimioterapia não procede à colheita de amostras de sémen antes do início 
do tratamento, pelo que a integridade dos espermatozoides recolhidos após o início do 
tratamento com etoposido pode ser preservada com a adição de NAC. Assegurando assim, 
que a maioria das células viáveis teria a integridade de DNA preservada e poderia ser 
utilizada com segurança em futuras técnicas de Reprodução Medicamente Assistida. No 
entanto, apesar destes resultados promissores, mais estudos devem ser realizados para 
confirmar a eficácia in vivo destes resultados e identificar uma terapia complementar eficaz 
que seja capaz de proteger a fertilidade masculina dos efeitos secundários causados pela 
quimioterapia. Até que tal terapia esteja disponível, é fundamental que todas as opções de 
preservação da fertilidade masculina sejam discutidas com os pacientes antes do 
tratamento ser iniciado, para assim permitir uma futura paternidade. 
 
 
Palavras-chave: Antioxidante; Espermatozoides; Etoposido; Infertilidade masculina; 
NAC; Quimioterapia. 
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Abstract 
Cancer has been affecting a growing number of children, adolescents and adult males 
in reproductive age. Male reproductive potential is adversely affected by chemotherapeutic 
drugs and patients are at risk for prolonged infertility. Etoposide is a chemotherapeutic drug 
used in the treatment of several neoplasia. It is a semi-synthetic agent, which acts via 
topoisomerase II inhibition, highly increasing the number of covalent DNA cleavage 
complexes, what results in permanent double-stranded breaks. Besides its interaction with 
topoisomerase II, it may also cause DNA damage by oxidative stress induction. Etoposide 
is known to affect spermatogenesis, and fertility recovery after drug exposure is associated 
with the dose used and treatment length, thus being difficult to predict. As a result, there is 
a strong need to identify a compound able to preserve male fertility during etoposide 
exposure without interfering with the efficacy of treatment. N-acetylcysteine (NAC), an L-
cysteine precursor, has chemopreventive and antioxidant properties. It has been 
demonstrated that this agent is safe for clinical use and has several protective effects on 
cells. Furthermore, studies have shown that NAC improves semen parameters and protects 
Sertoli cells from damage induced by oxidative stress due to its antioxidant potential. As 
NAC has been reported to possess cytoprotector properties, we hypothesized that it may 
be a good preserver of sperm quality during short-term etoposide exposure.  
In our experiments, human spermatozoa were incubated for 2 h at 37 ºC with 25 
µg/ml of etoposide, 50 µM of NAC and both drugs in combination. Spermatozoa parameters, 
such as motility, vitality and morphology, as well as DNA fragmentation and chromatin 
condensation were evaluated. Oxidative damages were measured and sperm metabolism 
was studied by proton nuclear magnetic resonance spectroscopy (1H-NMR). Our results 
demonstrate that short-term exposure to etoposide induces chromatin alterations and DNA 
fragmentation. Moreover, etoposide does not induce sperm oxidative damages nor 
glycolytic profile alterations. The addition of NAC to sperm exposed to etoposide preserved 
sperm morphology and chromatin condensation and reduced sperm DNA fragmentation.  
Thus, although short-term exposure to etoposide does not affect sperm vitality, it 
induces severe chromatin alterations and DNA damages to human spermatozoa. Besides 
these alterations may compromise male fertility, being potentially transmittable to the next 
generation. The addition of NAC to sperm exposed to etoposide protected cellular 
chromatin integrity and reduced DNA fragmentation. Therefore, it acts as a cytoprotector 
agent, shielding human sperm DNA from etoposide-induced damages. A short-term 
exposure of human spermatozoa to etoposide does not induce cellular oxidative damages 
nor glycolytic profile alterations, providing evidence that etoposide directly affects sperm 
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DNA. NAC’s ability to preserve human spermatozoa from DNA damages induced after a 
short-term exposure to etoposide may be of clinical relevance. The majority of patients 
undergoing chemotherapy fail to collect semen samples prior to the initiation of treatment, 
therefore, the integrity of the collected spermatozoa after etoposide treatment initiation 
could be preserved with the addition of NAC, assuring that the majority of viable cells would 
have their DNA integrity preserved and could be safely used in Medically Assisted 
Procreation. Although results are promising, further research must be implemented to 
identify an effective supplemental therapy that addresses the multiple side effects of 
chemotherapy on male reproductive function. Until such therapy is available, it is 
fundamental that all fertility preservation options are discussed with patients, before 
treatment is initiated, to allow parenthood. 
 
 
Key-words: Antioxidant; Chemotherapy; Etoposide; Male infertility; NAC; Spermatozoa. 
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Abstract: Cancer has been affecting a growing number of children, adolescents and adult males in 
reproductive age. Male reproductive potential is adversely affected by chemotherapeutic drugs and 
patients are at risk for prolonged infertility. Fertility recovery is related to the chemotherapeutic agent 
and dosage used, being thus difficult to predict. As a result, there is a strong need to identify a natural 
or synthetic compound that is able to preserve male fertility without interfering with the efficacy of the 
chemotherapeutic regimen. New procedures, as well as several drugs, are being investigated to 
assess their efficiency in protecting male reproductive functions from the chemotherapy side-effects. 
This review provides an overview of the wide range of chemotherapeutic drugs regularly used in 
cancer treatment and their detrimental effects on male fertility. In addition, it also assesses the 
existing protector agents for male fertility and their usefulness in preserving and protecting male 
reproductive functions exposed to chemotherapeutics. Several protector agents for male fertility are 
being studied, and results are promising. Nonetheless, further research must be implemented to 
identify a supplemental therapy that addresses the multiple side effects of chemotherapy on male 
reproductive function. Until such therapy is discovered, it is fundamental that all fertility preservation 
options are discussed with patients, before treatment is initiated, to assure parenthood. 
 
Keywords: male infertility; chemotherapy drugs; cytoprotector agents; antioxidants; hormone 
therapy.  
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1. Introduction 
The global cancer burden has been increasing over the last decades. There is striking 
evidence of a growth in cancer incidence among children and adolescents. In fact, 
approximately 15% of male cancer patients are 55 years of age or younger, and 25% of 
those are still below their twenties (1). Chemotherapy and radiotherapy regimens allow the 
survival of a higher number of patients and, these days, the majority of children and 
adolescents who have been diagnosed with cancer can truthfully hope for long-term survival 
(2-4). With increasing survival rates, the concern with the life quality of the surviving patients 
is a crucial issue (5). The cytotoxic chemotherapy is associated with substantial morbidity 
(6). The testes are highly vulnerable to chemotherapy toxicity and hence, alterations in 
gonadal functions that might impair male fertility are one of the most common treatment 
side effects (5, 6). Chemotherapeutic drugs target preferentially the cellular cycle, thus 
being highly detrimental for male spermatogenesis, damaging the germinal epithelium and 
decreasing sperm quality (7). 
Spermatogenesis is a complex biological process that begins in the testes of pubertal 
men. It comprehends the entire development course of a diploid stem cell, the 
spermatogonium, to a very specialized haploid cell with unique characteristics, the 
spermatozoa. This process occurs within the seminiferous tubules for a length of around 70 
days and produces approximately 70 million spermatozoa daily (8). Spermatogonia are 
located on the basal membrane of the seminiferous tubules and are the precursors of all 
male germ cell types. These cells are responsible for the initiation of the spermatogenesis 
process, undergo continuous self-renewal by mitosis and regulate cell population ensuring 
an appropriate balance between germ cells and Sertoli cells (9). Spermatogonia can be 
divided into two different types, A and B, depending on their heterochromatin content. Type 
B spermatogonia have a higher amount of heterochromatin, an indication of a differentiating 
cell, and are consequently the precursors of spermatocytes (8-10). The spermatocytes 
cross the blood-testis barrier, formed by the Sertoli cells tight junctions, and go through 
meiosis. During the course of meiosis there is an exchange of genetic material between 
homologous chromosomes that then migrate to separate cell poles and give origin to 
secondary spermatocytes at the end of meiosis I. Then these secondary cells undergo the 
second phase of meiosis forming four haploid round spermatids (11). Once meiosis is 
completed, spermatids experience spermiogenesis, differentiating into elongated, 
condensed, mature spermatozoa, that are released in the lumen of the seminiferous tubules 
(8). 
Although spermatogenesis is maintained throughout life, cytotoxic chemotherapy and 
radiotherapy may cause persistent damage and lead to transient or persistent oligospermia 
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and azoospermia (12, 13). Fertility recovery is related to the chemotherapeutic drug taken 
and the dosage used, thus being very difficult to predict. In fact, up to 30% of juvenile cancer 
survivors persist sterile for the remaining of their lives (14). For that reason efforts have 
been made to discover new approaches to maintain the reproductive health of such 
patients. However, to this day, there is no pharmacological protocol to prevent or diminish 
the damage induced by chemotherapy on spermatogenesis (15). 
Semen cryopreservation is so far the most common approach to face this problem. 
Even though it offers patients a chance to preserve their fertility, it presents some limitations. 
Firstly, pre-pubertal boys are unable to produce mature spermatozoa and although 
testicular tissue of the undeveloped testes contains spermatogonial stem cells that have 
been able to re-establish fertility after transplantation in mammals (16), further technological 
development is still required before it can be applied to humans (17, 18). In addition, semen 
parameters in cancer patients are often altered even before the initiation of treatment (19). 
Moreover, in order to achieve the best results possible, cryopreservation must be performed 
before the chemotherapeutic regimen is initiated and several samples should be preserved 
(18). Nonetheless, studies have shown that oncologists and their patients frequently do not 
consider this option until therapy has begun (20). Consequently, efforts have been made to 
determine new procedures that are capable of protecting spermatogenesis and 
spermatozoa from the adverse effects of chemotherapy (6, 12). 
 
2. Adverse effects of chemotherapeutic drugs on male fertility 
Chemotherapeutic drugs target mainly dividing cells, being very detrimental for male 
spermatogenesis (Figure I-1). These agents can easily reach the proliferative epithelium of 
the seminiferous tubules and some can even infiltrate the blood-testis barrier and harm the 
later stages of differentiating germ cells, which are very susceptible to cytotoxic agents (21). 
Gonadotoxic therapies are used not only in cancer treatment but in other disorders, such 
as autoimmune diseases, myelodysplatic syndromes and bone marrow transplants (7, 22). 
The risk of infertility due to these treatments is related to the drug, dose and length of period 
for which the drug is used (3). The chemotherapeutic drugs used in the clinical practice can 
be divided into different categories according to their origin and means of action.  
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Figure I-1. Schematic illustration of spermatogenesis and the detrimental effects triggered by 
chemotherapeutic drugs. Sertoli and developing germ cells compose the seminiferous epithelium 
while Leydig and myoid cells are located in the interstitial space. Spermatogenesis is the process in 
which the male gametes, spermatozoa, are produced. Sertoli cells constitute the physical and 
nutritional support of the developing germ cells. Type A spermatogonium divides and develops into 
type B spermatogonium, which enters meiotic prophase and differentiates into primary spermatocyte 
which in turn undergoes meiosis I and forms the secondary spermatocyte. After meiosis II is 
complete, four haploid spermatids migrate toward the lumen, where fully formed spermatozoa are 
finally released. Chemotherapeutic agents can disrupt spermatogenesis by directly interacting with 
testicular cells, causing cellular metabolism dysregulation, protein dysfunction, genetic damages and 
cellular death.  
 
 
2.1 Alkylating Agents  
The first chemotherapeutic agent to obtain approval for use in the clinical practice was 
an alkylating drug. Alkylating agents are electrophilic elements that interact with the 
functional group of nuclear proteins or DNA, covalently transferring alkyl groups (CnH2n+1).  
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 Consequently, alkylating agents lead to protein inactivation or cytotoxic DNA strand 
breaks (42-44). They are used in the treatment of diverse cancers types, like lymphoma, 
Hodgkin disease, non-Hodgkin’s lymphoma, leukaemia and sarcomas (42). These 
chemotherapeutic agents are highly detrimental to cells and carry numerous side effects on 
male fertility (Table I-1). 
 
Chlorethamine and chlorambucil are two alkylating agents that belong to the group of 
nitrogen mustards, which present a high risk for prolonged azoospermia after treatment. 
Chlorethamine is typically used in combination therapies for the treatment of Hodgkin 
disease and non-Hodgkin’s lymphoma. Studies have shown that therapies employing 
chlorethamine as the main agent exhibited up to 97% of azoospermia after treatment and, 
for the majority of the patients, the recovery rate of spermatogenesis was slow, with a 
decade of spermatogenesis hiatus (23, 24). Furthermore, chlorethamine regimens have 
shown to decrease sperm concentration and by the end of patient follow-up there was still 
Table I-1. Alkylating agents and their detrimental effects on male fertility 
Chemotherapeutic 
drug 
Formula Effect on male fertility 
Infertility 
Risk 
Study 
Type 
Species 
Chlorethamine C5H11Cl2N 
Prolonged azoospermia 
Reduced sperm count and 
motility 
High In Vivo Human (23, 24) 
Chlorambucil C14H19Cl2NO2 Prolonged azoospermia High In Vivo Mouse (25, 26) 
Cyclophosphamide C7H15Cl2N2O2P 
Prolonged decrease in sperm 
count or azoospermia 
High 
In Vivo 
Mouse (27) 
Human (28) 
In Vitro Rat (29) 
Ifosfamide C7H15Cl2N2O2P Prolonged azoospermia High In Vivo 
Rabbit (30) 
Human (31) 
Busulfan C6H14O6S2 
Damage stem and 
differentiating spermatogonia 
Likely to cause prolonged 
azoospermia 
High In Vivo Mouse (32, 33) 
Carmustine (BCNU) 
C5H9Cl2N3O2 Azoospermia after pre-pubertal 
treatment 
High In Vivo 
Mouse (34-36) 
Rat (37) 
Lomustine (CCNU) 
C9H16ClN3O2 Damage differentiating 
spermatogonia 
High In Vivo Mouse (34, 36) 
Carboplatin C6H12N2O4Pt 
Damage spermatogonia, Sertoli 
cells and  spermatozoa 
membranes 
Moderate 
In Vivo 
Mouse (38) 
Rat (39) 
Temporary azoospermia 
Human (40) 
In Vitro Human (41) 
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no evidence of motile spermatozoa (23). Chlorambucil is an antineoplastic and 
immunosuppressive agent mainly used in the treatment of lymphomas and immunological 
disorders (26). An in vivo study in mice treated with chlorambucil has shown that these 
agent induced heritable mutations in germ cells, especially in early spermatids (25). 
Chlorambucil is very detrimental for spermatogenesis being highly cytotoxic for male 
spermatogonia and capable of inducing chromosomal aberrations in spermatids and 
spermatozoa, which leads to a prolonged state of azoospermia after treatment (26). 
Cyclophosphamide and ifosfamide are synthetic forms of nitrogen mustards that in 
comparison to their precursors are more stable and less toxic to cells. These two pro-drugs 
are normally used in the treatment of various solid tumours and sarcomas. However, they 
have a wide range of side effects, including prolonged azoospermia, especially thanks to 
their metabolites (42). Studies conducted in mice that underwent different cycles of 
cyclophosphamide treatment showed that this drug is responsible for a decrease in all the 
differentiated cells of the testis (27). In male rats, it was demonstrated that germ cells with 
DNA damage, due to cyclophosphamide exposure, pursued spermatogenesis and 
produced damaged spermatozoa, which may affect the pregnancy success rate (29). In 
humans, it has been described that cumulative doses of cyclophosphamide are more likely 
to cause long term sterility than a single dose treatment (28). Ifosfamide is mainly used in 
combination with other antineoplastic agents. Nonetheless, a study with rabbits assessed 
the effects of ifosfamide, as a single agent, on male fertility. This study revealed that varying 
dosages of ifosfamide cause transient and dose-dependent oligospermia (60, 90, 120, and 
240 mg/kg), teratozoospermia (120 and 240 mg/kg) and asthenozoospermia (240 mg/kg). 
Furthermore, spermiogenesis was decreased with dosages of 60, 90, and 120 mg/kg of 
ifosfamide, while spermatocytogenesis and sperm maturation in the epididymis were 
severely affected at the highest dosage tested (240 mg/kg) (30). Ishikawa and colleagues 
evaluated cancer patients treated with a high-dose chemotherapeutic regimen, where 7.5 
g/m2 of ifosfamide was used in combination with other agents. Their results showed that 
although the majority of patients exhibited spermatogenesis arrest during treatment and 
were considered azoospermic, in the follow up 50% of the men were normospermic (31). 
Busulfan is the only alkyl alkane sulfonate used in the medical field. It is an 
antineoplastic and immunosuppressive agent with myeloablative properties mostly used for 
allogeneic hematopoietic progenitor cell transplantation in patients with chronic myeloid 
leukaemia (42). The cytotoxic activity of this drug is attributable to its ability to induce DNA-
DNA and DNA-protein cross links. A study on mice exposed to bulsufan has demonstrated 
that it is able to accelerate the germ cell apoptotic rate, and that a single dose of 40 mg/kg 
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is capable of completely abolish the male germinal epithelium (33). In fact, with doses this 
high, mice became permanently sterile (32). 
The group of nitrosoureas alkylating agents, of which carmustine (BCNU) and 
lomustine (CCNU) are part of, are very effective anti-proliferative drugs that have the ability 
to cross the hemato-encephalic barrier (42, 45). Hence, these agents are primarily used in 
the treatment of brain tumours, but are also used to treat melanomas and some carcinomas 
(42). BCNU and CCNU are agents with elevated gonadotoxicity and sterilizing capability, 
both in pre-pubertal boys and adults. These two drugs are responsible for the induction of 
mutations throughout all stages of spermatogenesis in a dose dependent manner (36). 
When administered at high doses (500 mg/m2 to 1 g/m2) they cause azoospermia, while in 
lower dosages they are usually given as part of a combined therapy with other highly 
sterilizing agents (46). Studies have shown that BCNU not only affects the spermatogonia, 
but is also capable of crossing the blood-testis barrier reaching spermatocytes and 
spermatids (34). Tates and collaborators described that BCNU is able to, in addition to 
producing chromatid aberrations in spermatogonia, cause translocations in spermatocytes 
(35). Research on rat models also revealed that, although female reproductive capacity is 
not affected by BCNU, males presented a disrupted reproductive aptitude during and after 
treatment. Moreover, a high percentage of male rats had ceased spermatogenesis and the 
frequency of embryonic loss was elevated (37). 
Carboplatin is a platinum analogue frequently used in chemotherapeutic regimens of 
neoplasia that affect young people and children. This chemical is highly stable, which 
confers a lower reactivity with DNA, thereby being less cytotoxic (47). However, a superior 
dose is required to obtain binding to DNA and effective antineoplastic activity (48). The 
effects of carboplatin on male mice testes have been investigated by Kopf-Maier and peers, 
which discovered that this agent affects fertility. Even though it is less reactive with DNA, 
the high doses needed to obtain the desired antineoplastic effects make it as toxic to cells 
as other commonly used alkylating drugs (38). Fuse and peers obtained similar results on 
male rats with carboplatin being harmful to spermatogenesis, specially affecting 
spermatogonia and Sertoli cells (39). Reiter and peers performed an in vitro study with 
human spermatozoa and found that carboplatin is responsible for significant damage on 
sperm membrane integrity (41). However, humans exposed to carboplatin present a high 
percentage of spermatogenesis recovery after treatment (40). 
 
2.2 Cytotoxic Antibiotics 
Cytotoxic antibiotics are drugs of microbial origin highly effective as antineoplastic 
agents. They are non-phase-cycle specific and act by interfering with DNA replication 
Article I 
11 
Fertility preservation in chemotherapeutic patients 
 
 
 
 
causing the arrest of the cell cycle. However, their complete mechanism of action is still not 
completely understood (49, 50). The information regarding the toxicity mechanism of these 
antibiotics is divisive. Some studies suggest these agents form free radicals in cells, induce 
DNA damage and enhance lipid peroxidation, while others found contradictory results (51). 
Despite all these uncertainties, there are several pathologies were these agents are 
prescribed, like lymphomas, leukaemia, sarcomas and testicular carcinomas (49-51). In 
Table I-2 we have summarized cytotoxic antibiotics and their risks for male fertility. 
 
The most frequently used cytotoxic antibiotic in oncological treatment is doxorubicin. 
It is an anthracycline antibiotic widely used in the treatment of oncologic diseases such as 
leukaemia, neuroblastoma, sarcomas and other malignant tumours (53). Furthermore, it is 
commonly implemented in the oncological treatment protocols of pre-pubertal patients (2, 
62). This drug is a very effective antineoplastic agent due to its aptitude to block DNA and 
RNA polymerase activity, inhibit topoisomerase II and interfere with chromosomal stability, 
thus ending DNA and RNA synthesis and blocking the cell cycle (53, 63, 64). As a result, 
several studies have been done to determine its implications on male fertility. Research 
conducted in mice has shown that doxorubicin is responsible for, in a dose dependent 
manner, reducing sperm count, motility and morphology (52). Furthermore, this drug also 
affects the structure and function of Sertoli cells and prevents spermatids from entering the 
spermiogenesis phase (52). Similar results were also described for male rats (54). 
Vendramini and collaborators tested the gonadotoxic effects of doxorubicin on male rats, 
and have observed that this drug is damaging to the seminiferous epithelium. Furthermore, 
in the follow-up of adult rats treated with doxorubicin, they discovered that this agent is also 
Table I-2. Cytotoxic antibiotics and their detrimental effects on male fertility 
Chemotherapeutic 
drug 
Formula Effect on male fertility 
Infertility 
Risk 
Study 
Type 
Species 
Doxorubicin C27H29NO11 
Killed stem and differentiating 
spermatogonia 
Reduced sperm count and 
motility 
Moderate In Vivo 
Mouse (52) 
Rat (53, 54) 
Dactinomycin C62H86N12O16 
Damaged spermatogonia and 
spermatids 
Reduced sperm count 
Low In Vivo 
Mouse (34) 
Human (55) 
Bleomycin C55H84N17O21S3+ 
Reduced sperm count and 
viability 
Low 
In Vivo 
Mouse (56)  
Rat (57-59) 
Human (60) 
In Vitro Mouse (61) 
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responsible for an increase in embryo loss, probably due to genetic abnormalities in 
spermatogonia (53). 
Dactinomycin acts as an inhibitor of nucleic acid synthesis, preventing production of 
DNA and RNA, being also capable of stopping protein synthesis, by interrupting the peptide-
chain elongation or preventing the attachment of oligosaccharide side chains to 
glycoproteins (65, 66). Dactinomycin is implemented as a single agent or in combination 
with other chemotherapeutics in several treatment protocols for children, young adults and 
adults, being responsible for high cure rates in Wilms tumour, rhabdomyosarcoma and 
Ewings sarcoma (67). Even with a high cure success rate, its effects on fertility must be 
taken into consideration when prescribing such antibiotic. Dactinomycin is capable of 
penetrate the blood-testis barrier, directly affecting all germ cells (34, 68). Studies in mice 
have shown that dactinomycin preferentially eliminates spermatogonia A and is responsible 
for alterations in spermatogenesis that yield deformed round spermatids with a diploid 
nuclei. As a result, the administration of these agent single-handedly reduced sperm count 
(34). Follow-up of male patients after treatment with combination therapies with 
dactinomycin revealed an infertility rate of 28% (55). 
Bleomycin is mainly employed in the treatment of squamous cell and testicular 
carcinomas, lymphomas, malignant pleural effusions and ascites (69, 70). This cytotoxic 
antibiotc exerts its antineoplastic activity by interacting with nucleic acids and proteins, 
leading to chromatin cleavage and cellular death (71). In vitro studies conducted by Liu and 
collaborators on mice, revealed that this drug is capable of directly damaging germ cells’ 
DNA, including the telomere region (61). Data obtained on rats supported the previous 
findings and revealed that this agent induces genetic and epigenetic mutations in all male 
germ cell types (56, 59) and, as a result of germ cell depletion, alters testis histology (57). 
Though studies have shown that bleomycin is gonadotoxic, its effects are usually temporary 
and normal spermatogenesis is regained a few months after treatment (58). The evaluation 
of men exposed to chemotherapies with bleomycin presented similar results, with bleomycin 
causing only temporary azoospermia (60). 
 
2.3 Antimetabolites and related therapy 
Antimetabolites and related therapy are effective antineoplastic agents, with moderate 
toxicity, normally used in combination with other chemotherapeutics to achieve a more 
effective regimen, due to substances synergism (72). Antimetabolites are elements that 
mimic a natural occurring molecule of the cell and interfere with all surrounding physiological 
pathways (73). By interfering with cell metabolism, these drugs are capable of altering cell 
functions. Antimetabolites that specifically target cell pathways, crucial for tumour growth, 
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can induce cellular arrest and death (74). There are some antimetabolites with 
antineoplastic activity that are routinely used in the medical practice to treat leukaemia and 
a number of solid neoplasia (72, 73, 75). These agents have several detrimental effects on 
male fertility (Table I-3).  
 
Cytarabine (Ara-C) is one of the most effective agents in the management of acute 
leukaemia and other hematopoietic malignancies. Its effectiveness as antineoplastic agent 
is the result of its ability to interfere with DNA polymerases and incorporate into DNA strands 
(96). Hence, Ara-C is capable of inhibiting DNA synthesis, leading to DNA fragmentation 
and consequently cell apoptosis (96, 97). Even though this drug is widely used in the 
treatment of children with leukaemia, it conveys many side effects. In males, the testes are 
particular affected. In vivo studies performed in male rats revealed that the sole 
administration of this agent modifies the testes histology and is responsible for a reduction 
in sperm count and quality. Moreover, Ara-C (50 to 200 mg/kg/day) diminished 
spermatogonia proliferation, delaying the start of spermatogenesis (78). When investigating 
the effects of Ara-C on male mice, Palo and peers (76) confirmed previous results and 
reported that Ara-C (100, 150 and 200 mg/kg) is liable for high percentages of abnormal 
spermatogonia and primary spermatocytes in the seminiferous tubules, as well as an 
elevated numbers of atypical sperm in the epididymis (77). 
Another antimetabolite commonly used in cancer treatments is 5-fluorouracil (5-FU), 
an agent from the fluorinated pyrimidines family, specifically designed according to scientific 
data of tumour biochemistry (98, 99). Despite being highly effective and routinely used 
Table I-3. Antimetabolites and related therapy and their adverse effects on male fertility 
Chemotherapeutic 
drug 
Formula Effect on male fertility 
Infertility 
Risk 
Study 
Type 
Species 
Cytarabine (Ara-C) C9H13N3O5 
Altered testes histology 
Reduced in sperm count and 
quality 
Moderate 
In Vivo 
Mouse (76, 77) 
Rat (78) 
In Vitro Mouse (77) 
5-Fluorouracil  
(5-FU)  
C4H3FN2O2 
Damaged spermatogonia and 
spermatocytes  
Reduced sperm count and quality 
Moderate In Vivo 
Mouse (34, 79)  
Rat (80, 81) 
6-Mercaptopurine  
(6-MP) 
C5H4N4S 
Damaged to spermatids  
Reduced sperm count 
Low In Vivo 
Mouse (34, 82)  
Human (83-85) 
Methotrexate (MTX) C20H22N8O5 
Testicular toxicity  
Germinal cell line degeneration  
Reduced sperm count and quality  
Oligospermia 
Moderate In Vivo 
Mouse (34, 86-90) 
Rat (91, 92)  
Rabbit (93)  
Human (94, 95) 
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against head, neck and gastrointestinal tumours, it is known that this antimetabolite induces 
chromosomal aberrations and mutations. In addition, it is a potent gonadotoxic that causes 
testicular damage, halts cell maturation and leads to the formation of deficient spermatids 
(81). In fact, several studies in rats have shown that 5-FU toxic side effects are dose-
dependent, causing the shrinkage and atrophy of the seminiferous tubules and altering 
spermatogenesis eventually leading to a significant decreased in sperm count (80, 81). 
Likewise, results obtained in male mice demonstrated that a single dose administration of 
5-FU induced a statistically significant number of DNA mutations in spermatogonia and 
spermatocytes, eventually killing the latter, in addition to altering sperm morphology. These 
findings suggest that the mutations induced by this drug in spermatogonia disrupt the 
complete course of spermatogenesis, ultimately affecting spermatozoa (34, 79). 
6-mercaptopurine (6-MP) is a purine antagonist generally used in the treatment of 
pre-pubertal acute lymphoblastic leukaemia (82, 100) and in the management of bowl 
diseases (84, 85). The daily administration of this drug in combination with other cytotoxic 
chemotherapeutics lengthens the period of remission. In fact, 60% of the individuals treated 
with combination therapies including this drug are in complete remission after a 5 year 
period (100). This antimetabolite interferes with all biological mechanisms involving 
endogenous purines, crucial constituents of the cell genetic information. Through the 
formation of its intracellular metabolite, thioinosinic acid (C10H13N4O7PS), 6-MP leads to the 
inhibition of DNA, RNA and protein synthesis, exhibiting both cytotoxic and 
immunosuppressive properties (101). The detrimental effects of this chemotherapeutic on 
male fertility have been assessed in several studies. The administration of 6-MP to male 
mice has been linked with a general reduction in fertility. This drug compromised spermatids 
viability, being responsible for a decrease of as much as 25% in sperm count (34).  
Ultimately, its administration to male individuals resulted in a considerably high rate of 
embryonic reabsorption (82). The use of 6-MP in men that wish to become fathers is 
dubious. There are evidences that, if men are exposed to this agent within 3 months prior 
to conception, there are higher chances for foetus malformations and gestational 
complications (84, 85).  
One other drug specifically developed for the oncological treatment is methotrexate 
(MTX). It has several pharmacological properties, being not only an effective anti-
proliferative agent, but also an immunosuppressor and anti-inflammatory drug. This agent 
is a folate antagonist regularly used to treat malignancies, such as acute lymphoid 
leukaemia, osteosarcomas and bladder cancer (102, 103). Being a folate antagonist, this 
element binds to the dihydrofolate reductase enzyme, preventing the synthesis of purines 
and pyrimidines and consequently disrupting protein synthesis and leading to cell death 
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(104, 105). In males, spermatogenesis may be particularly affected by MTX, causing 
important fertility issues. Until now several studies have been conducted in many different 
species and there are quite a few case reports of the side effects of this drug on male fertility. 
While testing the toxic effects of MTX on male mice germ cells, Choudhury and peers 
discovered that, after intraperitoneal administration (2, 10 and 20 mg/kg) of this agent there 
was a significantly higher percentage of abnormal primary spermatocytes and 
morphologically altered spermatozoa (86). There were also some evidences that MTX acts 
as a clastogenic agent inducing cytogenetic alterations in spermatogonia, which were 
transmittable to sperm (86, 88). Other studies in mice confirmed previous results, allowing 
the classification of MTX as a clastogenic agent capable of causing DNA damage to male 
germ cells, reducing sperm count and overall quality and inducing general testicular toxicity 
(87, 89, 90). Results obtained on rats exposed to an intravenous administration (100, 300. 
500, 700 mg/Kg) of MTX also revealed that the lower and intermediate dosages tested may 
possibly lead to oligospermia, but do not cause testicular atrophy (91). These findings may 
be the result of minor changes in testicular histologic parameters, among an accentuated 
apoptosis of germ cells and compromised spermatogenesis, as demonstrated in rabbits 
(93) and in rats (92). Due to its diverse pharmacological properties, there are some case 
reports on the effects of MTX on human male fertility that may be useful to predict fertility 
on cancer patients after MTX treatment. In a 1993, a case report  described an infertile 
patient with psoriasis, presumably due to recurrent treatments with MTX (94). They reported 
that the fertility issues arose from genetic abnormalities and subsequent gene mutations 
triggered by this drug and recommended that male individuals should be counselled before 
initiating MTX therapy. A more recent report in a patient with severe Crohns’s disease had 
similar results, suggesting that this drug must not be prescribed to men trying to conceive, 
because of its presumable teratogenic properties, even though this not always seem to be 
the case and some men have perfectly healthy children (95). 
 
2.4 Vinca Alkaloids and other natural products 
Throughout human history, natural products have played a critical role in medicine. 
Plants have been studied for their pharmacological properties since the origin of civilization, 
but only recently their antineoplastic qualities have been assessed. Nowadays some 
phytochemicals are the main component of several chemotherapeutic regimens (106-108). 
Plants are a natural source for antineoplastic agents, there are plant produces that affect 
the overall male reproductive function (Table I-4). 
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 The first natural chemotherapeutic agents derived from plants to be developed and used 
in the clinical practice were the vinca alkaloids vinblastine (VBL) and vincristine (VCR). 
These agents are isolated from the Madagascar periwinkle, Catharanthus roseus, and are 
known to interfere with some biological functions (108, 122). Vinca alkaloids are cytotoxic 
agents capable of binding to tubulin preventing dimer polymerization and therefore 
interfering with the assembly of microtubules (109, 123). Hence, these agents have strong 
anti-proliferative properties due to general mitotic arrest (123, 124).  
VBL is a frequently used chemotherapeutic agent in the treatment of several 
malignancies, like germ cell cancers and Hodgkin’s lymphoma (109). This drug is capable 
of arresting the cell division cycle in metaphase, thereby inhibiting cell proliferation. 
Furthermore, VBL is known to induce aneuploidy and indirectly lead to chromosomal 
aberrations (124). Chemotherapeutic treatments with VBL have been related with the onset 
of azoospermia, which may be reversible after a period of 3 years in approximately half of 
the affected men (109). As a result, there is general concern on the reproductive and genetic 
integrity of these men and their progeny after treatment (109, 110). A study conducted on 
mice revealed that VBL is cytotoxic to male reproductive functions at different dosages. 
While analysing testicular weight, researchers found that, at dose of 1 mg/kg or higher, 
there was a significant decline in testicular weight. In addition, administration of VBL 
resulted in significant changes in germ cell populations (109). Recent reports on VBL 
genotoxicity disclosed that this agent is accountable for significant changes in the cell cycle, 
ultimately leading to an increase in various chromosomal aberrations in mice (110). Due to 
the known capacity of VBL to induce genetic damages that may be transmissible to the 
Table I-3. Vinca alkaloids and other natural products and their effects on male fertility 
Chemotherapeutic 
drug 
Formula Effect on male fertility 
Infertility 
Risk 
Study 
Type 
Species 
Vinblastine (VBL) C46H58N4O9 
Changes in germ cell 
populations 
Induction of chromosomal 
aberrations 
Moderate In Vivo 
Mouse (109, 110) 
Human (111) 
Vincristine (VCR) 
 
Changes of the seminiferous 
tubules 
Arrest of spermatogenesis at 
the spermatid phase 
Azoospermia 
Moderate In Vivo 
Rat (112) 
Human (60, 113-
115) 
C46H56N4O10 
Etoposide C29H32O13 
Temporary gonadal damage  
Distress of spermatogenesis  
Increased chromosomal 
abnormalities in sperm 
Moderate 
In Vivo 
Rat (116) 
Human (31, 117-
120) 
In Vitro Human (121) 
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offspring, Robbins and peers studied male patients that underwent treatment for Hodgkin’s 
disease with this drug. They described that in these patients there was an increase in 
spermatozoa with chromosomal defects (111).  
VCR is also a highly effective, cell cycle specific, chemotherapeutic agent often used 
in the treatment of diverse cancer types (125). Several studies have found that the VCR 
efficacy as an anti-proliferative drug rests on its concentration and duration of exposure, as 
well as on the amount of cancer cells in mitosis at the time of treatment (126). Despite its 
wide use in the clinical practice, VCR has some noticeable secondary side effects on male 
reproductive functions. A study conducted on male rats revealed that VCR significantly 
impaired male fertility and was responsible for seminiferous tubules histological changes 
(112). Furthermore, this drug was responsible for the arrest of spermatogenesis at the 
spermatid phase. Although most VCR-treated male rats recovered fertility several weeks 
after cessation of treatment, a third did not, and remained permanently sterile (112). In 
humans, VCR is routinely used as part of diverse combination therapies. Therapies 
containing VCR are usually implemented in patients with Hodgkin and non-Hodgkin 
lymphoma and are responsible for increased damages on male spermatogenesis (60). 
Rautonen and peers (115) studied the effects of VCR on male fertility and concluded that, 
this agent, when administered in children or young adults, may be the main culprit in causing 
possibly permanent azoospermia. In fact, therapy containing this agent is accountable for 
the extreme impact of treatment on human male fertility, which in most cases may be 
irreparable (113, 114).  
In addition to the chemotherapeutics from the vinca alkaloid family, there are several 
others that derive from natural products. Etoposide is a semi-synthetic agent that derives 
from the podophyllotoxin, extracted from a plant commonly known as Mayapple, 
Podophyllum peltatum (106, 127). This drug has long been used as a first-line agent in the 
treatment of numerous neoplasia, such as lung and testicular cancer, non-Hodgkin’s 
lymphoma, leukaemia and sarcomas (128), and was the first antineoplastic drug discovered 
to act via topoisomerase II inhibition (129). Topoisomerase II inhibitors are among the most 
powerful antineoplastic agents and are therefore used in multiple cancer types (130). 
Etoposide is a phase-specific, cytotoxic drug that acts by stabilizing the topoisomerase II 
complex with DNA, which directly results in DNA strand breaks and leads to cell death by 
apoptosis (131). Moreover, there are also evidences that etoposide does not only cause 
DNA breaks by topoisomerase II interaction, but also the formation of free radicals (132). 
Stumpp and peers (116) investigated the incidence of apoptosis in the seminiferous 
epithelium of adult rats treated with etoposide during the pre-pubertal phase. Their results 
revealed that this drug, when administered during the pre-pubertal phase impaired male 
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fertility. Etoposide is commonly implemented in the clinical practice as part of a combination 
therapy. Thus, many authors have followed etoposide treated patients and observed its 
consequences on male fertility. Ishikawa and peers have analysed the effects of etoposide 
in spermatogenesis and have described that its recovery after chemotherapy was only 
observed in some of the patients (31). Similar results have been attained by Stephenson 
and peers (118). On the other hand, a similar study found no significant permanent damage 
in the male gonads (117). However, the chemotherapeutic regimen followed was different 
what may explain these conflicting results. While analysing the genetic damage caused by 
etoposide in human spermatozoa, De Mas and peers found that there was an increase in 
the number of aneuploidies, probably due to etoposide mode of action (120). However, an 
analogous study found no increase in human sperm chromosomal abnormalities (119). 
Nonetheless, two times more spermatozoa per patient and chromosomes was analysed by 
De Mas and peers, what may explain the differing results between the two studies. In vitro 
studies on etoposide are scarce but revealed that this drug is capable of severely distressing 
human spermatozoa (121).  
Chemotherapy agents have a broad spectrum of damaging effects on male fertility. 
However, there is still the need to further study the majority of these agents in order to 
improve the treatment given to patients. In addition to the agents described in this review, 
several others may be affecting male fertility but are yet to be identified.  
 
3. Fertility preservation in men undergoing chemotherapy 
An ideal cancer treatment would only target malignant cells and would have no 
secondary effects on the gonads. However, most oncological drugs target mainly dividing 
cells, which makes them highly detrimental for germ cells and fertility, especially in the male. 
Even though therapeutic regimens are being constantly improved, with less gonadotoxic 
approaches, they are still harmful, and their outcome on male fertility is difficult to predict 
(5, 15).  
Currently, there are no complementary therapies available that are entirely effective 
in preventing damages caused by chemotherapeutics to male reproductive functions (12, 
133). Having this in mind, there is a clear need to discover agents capable of protecting 
male fertility during the chemotherapeutic regimens or agents that are able to restore normal 
reproductive functions after treatment completion. 
In general, chemotherapeutics affect the patient’s semen parameters, like 
concentration, motility and morphology, the spermatozoa genetic content, the overall 
testicular histology and the hormonal levels (31, 119, 134). The intensity of the damages 
typically rests on the chemotherapeutic drug and dosage used, as well as the treatment 
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length. All these factors also influence the reversibility of the damages and ultimately the 
recovery of fertility (14, 135). Antineoplastic agents affect non-cancerous tissues in different 
manners, so there is the need to find agents that act specifically on those pathways and are 
able to protect those cells. Hence, there are different strategies for male fertility preservation 
against the chemotherapy side-effects and protector agents can be assembled into different 
categories depending on their means of action (Figure I-2).  
 
 
Figure I-2. Fertility preservation strategies for males being treated with cytotoxic 
chemotherapies. Three preferential paths are being tested as fertility preservation options for males 
undergoing chemotherapy: antioxidant defence, hormone therapy and the use of cytoprotector 
agents. These paths focus on improving spermatozoa quality, preserving germ cells and protecting 
spermatogenesis. Abbreviation: ROS, reactive oxygen species; GnRH-A, gonadotropin-releasing 
hormone antagonist. 
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3.1. Antioxidants 
Oxidative stress has been identified as one of the primary causes of the 
gonadotoxicity of anticancer therapies. Reactive oxygen species (ROS) are naturally 
generated in vivo from dioxygen (O2). Although they are crucial players on several cellular 
processes, of which cell signalling is one of the most relevant, their derivatives, like 
hydrogen peroxide (H2O2) and hydroxyl radical (HO•), can be highly detrimental for tissues 
and cells (136, 137).  
There are numerous biological antioxidants and enzymes that are responsible for the 
preservation of cellular redox conditions. However, when there is an imbalance between 
ROS production and its elimination, cells enter in oxidative stress. This condition incites 
several oxidative reactions that ultimately may lead to cellular damage and death (136, 
138). 
More than 40% of all approved antineoplastic agents are known to induce oxidative 
stress both in cancerous and non-cancerous tissues. In fact, tissue damage due to oxidative 
stress is one of the most substantial side effects of chemotherapy (136). Oxidative stress is 
harmful to testis and spermatozoa being one of the hypothesised mechanisms responsible 
for male infertility (139, 140). Consequently, there is a growing number of antioxidants being 
tested in order to identify those with the highest potential in protecting the reproductive 
function of males undergoing chemotherapy (Table I-5). 
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Table I-5.  Antioxidants with protective effects against chemotherapy secondary effects on male 
fertility 
Antioxidant Formula Effects Efficiency 
Study 
Type 
Species 
Studied 
Astaxanthin 
(AST) 
C40H52O4 
Improved reproductive parameters 
Reduced chemotherapy induced 
DNA damaged  
High In vivo Mouse (141) 
Lycopene C40H56 
Normalized reproductive parameters 
Improved sperm concentration and 
motility 
Moderate In vivo Rat (142-144) 
Ellagic acid (EA) C14H6O8 
Decreased sperm abnormalities  
Improved sperm concentration and 
motility 
High In vivo Rat (144-147) 
α-Lipoic acid (LA) C8H14O2S2 
Normalized reproductive parameters 
Improved testicular histology 
Moderate In vivo Rat (148-150) 
1-N,4-N-
diphenylbenzene
-1,4-diamine 
(DPPD) 
C18H16N2 Improved testicular histology High In vivo Rat (151) 
Melatonin C13H16N2O2 
Improved testis histology 
Decreased induced 
spermatogenesis toxicity  
Improved the cytotoxic damages 
found on germ cells 
High In vivo 
Mouse (33, 152) 
Rat (153) 
N-acetylcysteine 
(NAC) 
C5H9NO3S 
Reduced lipid peroxidation  
Reduced chemotherapy induced 
oxidative stress 
Moderate In vivo Rat (151, 154) 
Vitamin C 
(Ascorbic acid) 
C6H8O6 
Protected male testes 
Partial reversion of gonadotoxicity 
Improved fertility recovery 
Moderate In vivo 
Mouse (155) 
Rat (151, 156, 157)  
 
Astaxanthin (AST) is an antioxidant from the carotenoid family. Antioxidants from this 
category function as important protectors of biological structures against oxidative stress 
mainly acting as free radical scavengers (158). AST is a naturally occurring antioxidant 
usually found in various crustacean species, algae and yeast. AST is capable of trapping 
free radical on the outer and inner cellular membranes thereby, effectively inhibiting lipid 
peroxidation (159). These characteristics make AST one of the most powerful antioxidants 
of its family. In fact, it has been reported that this antioxidant is 10 times stronger than others 
of its category (160). Its powerful antioxidant characteristics make it an ideal candidate to 
potentially protect cells from the damaging effects of oxidative stress. Taking this into 
consideration, Tripathi and Jena, studied the protective effects of AST against the 
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secondary effects of cyclophosphamide on male mice germ cells (141). These authors 
assessed several reproductive features and discovered that, as hypothesised, treatment 
with AST significantly improved testes histology and prevented the cyclophosphamide-
induced damage to spermatozoa, restoring their normal head morphology. Besides, AST 
was able to significantly reduce the germ cell’s DNA damage (141). 
Lycopene is another important antioxidant from the carotenoid family. This compound 
has very strong antioxidant properties and can be found at high concentrations in numerous 
fruits and vegetables, especially in tomato (161-163). Due to its structural configuration, 
lycopene is a potent antioxidant with high singlet-oxygen quenching capability that can 
reduce several oxidative stress biomarkers. Therefore, this compound can prevent free 
radicals from disrupting cellular balance, being highly beneficial for general health (164, 
165). Besides its antioxidant ability, there are many other positive features being 
investigated and studies have shown that lycopene appears to also have some anti-
proliferative and anti-carcinogenic activities (166, 167). It has also been tested as a 
supplemental treatment for human male idiopathic infertility and it has shown some 
promising results. Lycopene was capable of increasing sperm concentration and movement 
trough free radical scavenging ultimately improving gestation rates (168). Accordingly, 
several studies have been made on the hypothesis that lycopene can protect male 
reproductive functions from the oxidative assault of chemotherapy. Atessahin and peers 
(142) suggested that lycopene could protect rat sperm from cisplatin-induced toxicity. In 
their study, rats were treated with an intraperitoneal dose of 7 mg/kg of cisplatin. To observe 
the protective effects of lycopene they divided their experiment into two distinct groups. One 
group of animals was pre-treated with lycopene for ten days prior to cisplatin administration 
and the other received lycopene for five days after the cisplatin was administrated, both 
experimental groups received a dose of 4 mg/kg lycopene. The authors discovered that 
lycopene was able to generally improve the reproductive capacity of the male rats. 
However, the more significant results were found in the post-treatment group. In fact, rats 
treated with lycopene after cisplatin administration displayed a significant normalization in 
the sperm concentration, motility and morphology. In addition, the redox status of 
spermatozoa was also significantly improved by the post-administration of lycopene, with 
the regularisation in both malondialdehyde and glutathione levels. These results were later 
corroborated by Turk and peers (143, 144). These authors performed studies to assess 
lycopene ability to protect rat testes from two distinct drugs, cyclosporine A and cisplatin. 
They found that the simultaneous administration of lycopene with these drugs is able to 
successfully preserve the rat spermatozoa and testes histology, thereby preserving its 
reproductive capacity. 
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1-N,4-N-diphenylbenzene-1,4-diamine (DPPD) is a potent synthetic antioxidant. This 
compound is able to donate a hydrogen to a radical derivative thus breaking the 
autocatalytic cycle (169). DPPD acts as a free radical and peroxidation inhibitor (170). A 
study has been conducted on its ability to protect rat testes from the oxidative damage 
caused by cisplatin. Authors have found that DPPD is able to significantly reduce cisplatin-
induced oxidative stress and improve testes histology. When compared with other 
antioxidants, DPPD proved to be more effective in reducing the number of apoptotic 
testicular cells (151). 
Ellagic acid (EA) (2, 3, 7, 8-tetrahydroxy [1]-benzopyrano [5, 4, 3-cde] [1] benzopyran-
5, 10-dione) is a naturally occurring polyphenol present in a variety of fruits and vegetables. 
This compound has several biological activities beneficial for human health, among which 
its antiviral, anti-inflammatory and antioxidant properties are the most noticeable (171). The 
main quality responsible for this wide range of activities is its antioxidant and free radical 
scavenger capacity that has been extensively studied (172-174). Nonetheless, the exact 
antioxidant mechanism of action of this compound is still unclear (147). EA is constituted of 
four hydroxyl and two lactone groups, in which the first is known to intensify the antioxidant 
activity, preventing lipid peroxidation, and protecting cells from the damage induced by 
oxidative stress (145). Besides being on itself a remarkable antioxidant, its metabolites are 
also being studied for their antioxidant abilities (174). This distinctive trait makes EA one of 
the most interesting compounds to address while studying oxidative stress inhibitors. 
Several studies have been conducted in order to identify its protective effects on male 
gonads exposed to chemotherapy. Turk and peers (144, 145, 147) conducted numerous 
studies on the protective effects of EA against the detrimental effects induced to the male 
rat gonads by different chemotherapeutic drugs, such as cisplatin and cyclosporine. Their 
results revealed that EA amended the chemotherapy induced damages to testes, 
epididymis, seminal vesicles and prostate. Furthermore, this antioxidant decreased sperm 
abnormalities and improved its concentration and motility. The authors concluded that EA 
antioxidant skills were able to protect male rat reproductive capacity against oxidative stress 
and toxicity caused by the different chemotherapy regimens. Another study, conducted on 
male rats by Ceribasi and peers (146), evaluated the capacity of EA to protect the male 
reproductive organs when exposed to chemotherapy. EA provided significant protection to 
testicular tissue against therapy-related oxidative stress, reducing chemotherapy-damages 
to male gonads and testicular apoptosis. Nevertheless, authors found that EA was not able 
to reverse organ weights loss and deteriorated sperm parameters that resulted from 
chemotherapy administration (146).  
Article I 
24 
Fertility preservation in chemotherapeutic patients 
 
 
 
 
α-Lipoic acid (LA) is a small molecule with two potential isomers: R-LA and S-LA 
(175). This biological thiol antioxidant is naturally found in mitochondria were it mainly 
functions as an essential coenzyme in metabolic reactions (176). Its main biological 
functions are intimately associated with its antioxidant, anti-mutagenic and anti-
carcinogenic properties (175, 177). Once inside the cells, LA is quickly absorbed and 
transformed by cells were it can regenerate various endogenous antioxidants and be an 
effective ROS scavenger, with the ability to restore the cellular redox state (178). Several 
studies have been led in order to take advantage of these traits for the protection of male 
reproduction during chemotherapy. Results obtained on male rats exposed to cytotoxic 
antibiotics revealed that LA was able to minimize lipid peroxidation and enhance the 
quantity and quality of spermatogenesis. Furthermore, LA was likewise capable of reversing 
the morphological changes induced to the testicular architecture (150). A different study led 
by Selvakumar and peers (148, 149) on cyclophosphamide gonadotoxicity further 
elucidated the antioxidant abilities of LA. This study has shown that this compound can 
protect male rat testes and semen quality from the oxidative stress derived from 
chemotherapy. However, as so far all research on this compound has been performed on 
animal models, several studies on human cells and clinical trials must still be conducted 
before any clinically relevant conclusions can be drawn. 
Melatonin (N-acetyl-5-methoxytryptamine) is a biological molecule mainly synthetized 
in mammals pineal gland. Besides being largely produced in mammalian cells, melatonin 
has been reported in edible plants and bacteria (179, 180). It is one of the strongest 
endogenous antioxidants, playing a crucial role in immune response and cell signalling 
(181, 182). Its antioxidant properties have been related to an improvement in the male 
reproductive dysfunctions related to diverse pathological conditions and exposure to toxic 
agents (183). Melatonin’s antioxidant activities can be partly explained by its ability to fuel 
antioxidant enzymes (184), thereby inhibiting lipid peroxidation and DNA damage brought 
on by oxidation (185). It has also been reported that this molecule can inhibit cell 
proliferation and boost tumour cell apoptosis, consequently having an antineoplastic effect 
(186). Melatonin can easily penetrate biological membranes and so it can directly protect 
the intracellular complexes from ROS-induced damage (187). A study using this molecule 
has reported that, due to its antioxidant influence, the in vitro incubation of human 
spermatozoa with a 2 mM dose can improve the percentage of motile spermatozoa and 
reduce the number of non-viable cells (188). Several other studies have been performed to 
assess if melatonin’s antioxidant properties can in fact shield male fertility from the damages 
caused by chemotherapy. A study done using male rats treated with cyclophosphamide and 
cisplatin, revealed that melatonin (10 mg/kg) protects the male gonads from chemotherapy-
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induced damage. In this study, melatonin was able to increase glutathione levels and 
glutathione peroxidase activity. Furthermore, this compound was able to prevent the 
histopathological changes provoked by the chemotherapeutic regimen (153). One other 
study using male mice treated with cyclophosphamide obtained similar results. Mice were 
exposed to different doses of melatonin (2.5, 5, 10, and 20 mg/kg) via intraperitoneal 
injection for five consecutive days prior to a single administration of cyclophosphamide (200 
mg/kg). Authors revealed that all melatonin dosages could considerably lessen the induced 
spermatogenesis toxicity in mice testes, likely due to its antioxidant properties (152). 
Mirhoseini and peers (33) obtained similar results while testing melatonin protective effects 
against busulfan-induced testicular damage on mice. Their results have confirmed that 
melatonin significantly reversed chemotherapy-induced cytotoxic damages on mice germ 
cells.  
N-acetylcysteine (NAC) is a derivative of the amino acid L-cysteine, which contains a 
thiol group, and has chemo preventive and antioxidant characteristics. It is an N-acetyl 
prodrug that acts primarily on the glutamatergic system (189). NAC is available either by 
prescription in intravenous and vaporizer forms or orally as an over-the-counter product 
(190). This compound is currently used as a mucolytic agent for patients with acute and 
chronic bronchitis, and as an antidote for paracetamol overdose (191). There are several 
other conditions where NAC use is being tested, however, the most promising result come 
from its chemopreventive features due to its antioxidant activity (192, 193). NAC exerts its 
antioxidant actions essentially by two mechanisms. It is capable of easily penetrating 
cellular membranes and, once inside the cells, it is a precursor in the biosynthesis of 
glutathione. When deacetylated it originates L-cysteine, further assisting glutathione 
synthesis (191, 192). In addition to its intracellular actions, NAC is capable of act at the 
extracellular level where it acts by directly scavenging free radicals (194). It has also been 
demonstrated that NAC has several positive protective effects on cells and studies on its 
potential toxicity have demonstrated its safety for clinical use (195, 196). Although extensive 
research has been made in the antioxidant protective effects of NAC on ROS-induced side 
effects (197-199), the amount of studies focused on male fertility is scarce. Yang and peers 
(154) evaluated the protective effects of NAC on Sertoli cell stress induced by sodium 
fluoride and discovered that this element was able to reduce endoplasmic reticulum stress 
via ROS inhibition, therefore protecting Sertoli cell functions. This compound has also been 
studied as a part of an antioxidant combination therapy. Ahmed and peers (151) evaluated 
NAC’s antioxidant activity against cisplatin-induced testicular oxidative damage in male rats. 
Their results showed that those antioxidants could significantly reduce lipid peroxidation 
and re-establish the cellular redox status. This study presented some very interesting 
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results that confirmed the potential of NAC antioxidant properties on preventing the 
gonadotoxic effect of chemotherapeutics. 
Vitamin C is an essential nutrient found abundantly in citrus fruits and in a diverse 
number of vegetables. This vitamin is the biologically active form of ascorbic acid, being 
responsible for the maintenance of connective tissues and bones (200). This compound is 
an important cofactor for a variety of enzymes and interacts with numerous transcription 
factors, regulating gene expression (201). Vitamin C is also an important antioxidant that 
functions as a potent reducing agent (202). Thanks to its properties, vitamin C is capable of 
reducing a variety of ROS both in intra and extracellular spaces (203). Due to the fact that 
both cancer and chemotherapy negatively affect men reproductive function partly by 
inducing oxidative stress and taking into account that vitamin C is a potent antioxidant, 
several studies have been conducted on its protective effects in male fertility (155-157, 204). 
When evaluating the shielding effects of vitamin C on testes of mice subjected to two 
chemotherapy cycles of cisplatin (1 and 2.5 mg/kg), Narayana and peers (155) concluded 
that it is in fact capable of partially reversing gonadotoxicity. A number of studies have also 
been conducted on male rats. Kilarkaje and peers (156) demonstrated that Vitamin C, in 
addition to other antioxidants, is able to protect rat testicular and reproductive functions 
against combination chemotherapy and increase the recovery process. These results are 
in agreement with those obtained in humans by Ahmed and peers and Das and peers, 
which likewise reported vitamin C to be beneficial in the maintenance and recovery of fertility 
of men exposed to different chemotherapeutic regimens (151, 157). 
In addition to all the elements and biological molecules previously described, there 
are several foods of natural origin that have strong antioxidant activity and are potential 
protectors of the chemotherapy-induced damage to male reproductive function. 
One natural compound known for its several pharmacological activities is royal jelly 
(RJ), a honeybee produce secreted from the glands of worker honeybees. This product is 
a natural source of proteins, sugars, lipids, vitamins and other nutrients (205, 206), and is 
known for its antioxidant and free radical scavenging abilities. Silici and peers (205) 
evaluated the potential protective effects of RJ against cisplatin-induced toxicity on rat 
sperm and presented some encouraging results. Authors reported that RJ could prevent 
the damaging effects to rat sperm brought on by cisplatin, via its antioxidant abilities.  
Coffee, and its key component caffeine, are another well-known natural produces with 
strong antioxidant properties that have been studied as a protector agent against oxidative 
stress on male fertility. This extremely popular beverage is one of the most consumed in 
the world and constitutes an important source for bioactive components with antioxidant 
features (207, 208). It has been shown that the antioxidant properties of this product are 
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important for human health and provide protection against oxidative stress in several organs 
(207, 209). Furthermore, caffeine can significantly reduce protein oxidation and lipid 
peroxidation in human Sertoli cells (210). Consequently, several studies have been 
performed in order to evaluate its free radical scavenging and anti-peroxidation activity as 
well as its capacity to protect cells from oxidative stress. A study conducted on male mice 
exposed to the chemotherapeutic cisplatin, revealed that caffeine could indeed protect 
testes from the damage provoked by this agent. The results obtained in this study led to the 
suggestion that caffeine may have an important role in the recovery process of male fertility 
after the oxidative damage prompted by chemotherapeutic agents (211). 
In addition to coffee, caffeine is also a major component of teas. Although tea has 
approximately 1.4 to 3.4 times less caffeine than coffee, there are several countries where 
tea is more appreciated and consumed and thereby the total amount of caffeine ingested is 
similar (210, 212). Tea is the second most consumed beverage in the world (213), and as 
a result several studies have been conducted on its antioxidant properties and beneficial 
effects for human health. Its positive effects on male reproduction have been assessed, and 
so far results have been encouraging (214, 215). In brief, the antioxidant capacities of tea 
must be taken into consideration for the protection of male fertility against oxidative stress 
induced, for example, by chemotherapy treatment.  
 
3.2 Hormone Therapy 
In general, chemotherapeutic drugs target rapidly dividing cells, what suggests that 
actively dividing germ cells are more susceptible to chemotherapy secondary effects than 
those of pre-pubertal patients (216). In fact, while analysing post-treatment patient recovery 
it is noticeable that children seem to regain gonadal function and fertility better than adults 
(217). Taking this into consideration, it has been hypothesised that by inducing a quiescent 
state to the testes with hormone therapy, germ cells would be less susceptible to the 
damaging effects of cancer treatment and therefore, male fertility would be preserved (2, 
218). 
Studies led on male rats by Pogach and peers (219) revealed that a pre-treatment 
combination of gonadotropin releasing hormone antagonist (GnRH-A) and testosterone is 
capable of preventing germinal aplasia induced by the chemotherapy. Furthermore, Glode 
and peers (220) have shown that the suppression of gonadal function in male rats by 
hormone therapy has the potential to protect germ cells of the damaging effects of 
procarbazine. Moreover, Meistrich and peers and Kurdoglu and peers pre-treated male rats 
with GnRH-A and anti-androgen flutamide, describing that it could significantly protect 
spermatogonia from chemotherapy side effects (221, 222).  
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Despite the promising results of animal studies, clinical trials have not been as 
convincing. In a human clinical it was reported that testosterone administration prior and 
during chemotherapy could potentially preserve fertility in men (216). These results were 
later seconded by research carried out by Cigni and peers (217). They treated men 
receiving a chemotherapeutic dose of cyclophosphamide with testosterone. Results 
showed that, although all men became azoospermic or oligospermic during treatment, the 
great majority regained a normal sperm count and follicle-stimulating hormone (FSH) levels 
after a twelve month period. Nonetheless, numerous other studies have found hormone 
therapy to have no protective effects on male gonads exposed to chemotherapy (223-225).  
 
3.3 Cytoprotector Agents 
Although chemotherapeutic agents are designed to attack neoplastic cells, the truth 
is that they are highly detrimental for various cell types, including normal cells. Therefore, 
there is a need to protect normal cells from these damaging effects.  
Trichloro(dioxoethylene-O,O') tellurite (AS101), an immunomodulator, is able to 
stimulate the production of numerous cytokines both in vitro and in vivo (226). Many of these 
cytokines have been described as protectors of the damaging effects induced by 
chemotherapeutic drugs. Therefore, AS101 is a competent cellular protector with diverse 
therapeutic applications (227, 228). This characteristic of AS101 has been the basis for 
suggesting that it may be capable of protecting the male reproductive cells from 
chemotherapy aggressions (229). Carmely and peers evaluated the effects of AS101 in the 
testes of male mice exposed to a dose of 200 mg/kg of cyclophosphamide (230). Their 
results showed that AS101 can in fact significantly protect male reproductive functions 
against chemotherapy-induced damage by significantly reducing the percentage of 
damaged seminiferous tubules and reducing sperm DNA fragmentation. 
Amifostine (C5H15N2O3PS) is an inorganic thiophosphate used in some treatment 
protocols with the aim of improving patient’s life quality. This agent can potentially protect 
cells by preventing the up-regulation of several inflammatory pathways induced by 
chemotherapy (231). Amifostine recognises cells’ physiological environment and can act 
preferentially on those with an abnormal expression of cellular metabolites (232). For that 
reason, amifostine can specifically protect normal cells, not interfering with the 
chemotherapeutic treatment. It has been hypothesized that this agent might be able to 
protect male fertility from the detrimental effects of chemotherapy. Lirdi and peers evaluated 
amifostine protective action against the damages induced by cisplatin on the testes of male 
rats (233). The results obtained confirmed that its administration before the 
chemotherapeutic treatment could substantially reduce testicular damage, partly by 
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reducing the number of apoptotic germ cells. Still, other studies described opposing 
outcomes. Vendramini and peers (234) evaluated the effects of amifostine against 
doxorubicin therapy in male rats and described that although the seminiferous epithelium 
damage was reduced, there was no particular improvement in the overall fertility status.  
 
4. Conclusion 
Cancer treatment has been improving over the last decades, pushing survival rates 
to their highest percentage ever. This brings the issue of patient’s life quality in the long run 
to the foreground. A focal point for the overall quality of life of patients is fertility. Fertility is 
highly important to the great majority of patients (235) and must be properly addressed 
before the gonadotoxic treatment is initiated. Chemotherapy side effects on male fertility 
are varied and is difficult to assess the individual risk for long term infertility. As a result, 
several fertility preservation options have been explored and must be discussed with 
patients.  
In order to achieve the best results possible in neoplastic treatment, the therapeutic 
regimens have been evolving with more effective drugs, generally used in combination. 
These regimens are more effective in the treatment of malignancies and tend to be less 
detrimental to male fertility. However, there are still a considerable number of side effects 
to have into consideration. To achieve a full recovery of sperm production after a cytotoxic 
insult, stem spermatogonia must be intact and resume their mitotic activity. However, 
several chemotherapeutic drugs deeply affect spermatogonia, permanently damaging its 
functioning. The complexity surrounding this issue led to the development of several 
preservation techniques, and to the exploration of a variety of compounds that could 
potentially protect male reproductive functions from chemotherapy-induced damage. 
Although results on protector agents seem to be promising, there is no certainties on 
their broad efficiency against chemotherapeutics. There is still the need for a wider research 
on each protector agent and its full activities on male germ cells when administered together 
with the various chemotherapeutic drugs. Therefore, in order to preserve the possibility for 
a future offspring, sperm cryopreservation must be offered before the initiation of treatment.  
In the future, further investigation on strategies for preserving male fertility must be 
pursued. One vital field of research is the discovery of new protector agents, and the 
investigation of combination supplemental therapies to address the multiple secondary 
effects brought on by chemotherapeutic regimens. Furthermore, all protector agents must 
be tested in extended clinical trials before definite conclusions can be drawn and they can 
be implemented as routine supplemental treatment. 
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Aims 
Chemotherapeutic drugs have a broad spectrum of secondary effects that can 
severely affect patients’ life quality. Even though etoposide is widely used in the clinical 
practice, the full range of its side effects has not yet been assessed, and studies on its 
consequences on male fertility are scarce. Consequently the first goal of our project was to 
analyse etoposide’s effects on human sperm parameters, sperm DNA, oxidative stress and 
metabolism after exposure in vitro.  
Citoprotection from chemotherapy seems the most reliable option for male fertility 
preservation so far. As a result we selected an antioxidant, NAC, as a possible protector 
agent for cells exposed to etoposide due to its clinical safe use and protective properties. 
Therefore, we aimed to evaluate NAC’s ability to preserve human spermatozoa from the 
damages induced by etoposide.  
For these purposes, human sperm samples were obtained and incubated for 2 h 
alone or in combination with our chemotherapeutic and antioxidant of choice. Microscopic 
sperm parameters, such as motility, morphology, vitality and viability were measured before 
and after the incubation period. The damages on sperm DNA were assessed by terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay and acidic aniline blue 
(AB) staining. Oxidative stress was evaluated by analysis of carbonyl groups, lipid 
peroxidation and 3-nitrotyrosine by the Slot-Blot technique. Protein carbonyl content was 
measured as a marker for protein oxidation, aldehyde products were indicators of lipid 
peroxidation and nitrotyrosines were a control for protein nitration. Lastly, spermatozoa 
metabolism was studied by Proton Nuclear Magnetic Resonance (1H-NMR). 
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Abstract: Etoposide is a chemotherapeutic used in the treatment of several neoplasias that affect 
males in reproductive age. Fertility recovery after etoposide exposure is associated with the dose 
used and treatment length, being difficult to predict. Therefore, there is a strong need to identify drugs 
able to preserve male fertility during etoposide exposure. N-acetylcysteine (NAC), a L-cysteine 
precursor, has chemopreventive and antioxidant properties. Others have shown that it improves 
semen parameters and protects Sertoli cells from oxidative stress-induced damages. Since NAC has 
been reported to possess cytoprotector properties, we hypothesized that it may be a good preserver 
of sperm quality during in vitro etoposide exposure. In our experiments, human sperm were 
incubated with 25 µg/ml of etoposide, 50 µM of NAC and both drugs in combination. Sperm 
parameters as well as DNA fragmentation and chromatin condensation were evaluated. Oxidative 
damages were assessed and sperm metabolism was studied by proton nuclear magnetic resonance 
spectroscopy (1H-NMR). Our results demonstrate that in vitro exposure to etoposide induced 
chromatin alterations and DNA fragmentation. Furthermore, etoposide did not induce sperm 
oxidative damages nor glycolytic profile alterations. The addition of NAC to sperm exposed to 
etoposide preserved sperm chromatin condensation and reduced DNA fragmentation. These results 
suggest that NAC can preserve sperm DNA integrity during etoposide treatment. Therefore, ensuring 
that for cancer patients who were not advised to cryopreserve sperm prior to chemotherapy 
treatment, will have sperm DNA integrity preserved and that sperm may be safely used in future 
Medically Assisted Procreation treatments. 
 
Keywords: Chemotherapy; Etoposide; Male fertility; Spermatozoa; Antioxidant; NAC.  
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Graphical Abstract: 
Protective effects of NAC to DNA integrity of etoposide-exposed sperm. 
 
Figure III-1. Protective effects of NAC on sperm DNA integrity.  
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1. Introduction 
Chemotherapeutic agents may interfere with spermatogenesis and cause long-
lasting infertility problems (236). Etoposide is a semi-synthetic agent that derives from the 
podophyllotoxin (132), widely used, alone or in combination, for the treatment of various 
neoplasias that affect males in reproductive age (237-239). It is mitotic phase-specific and 
it was the first antineoplastic drug to be discovered to act via topoisomerase II inhibition 
(129). This drug forms a stable complex between topoisomerase II and DNA, highly 
increasing the number of covalent DNA cleavage complexes, which results in permanent 
double-stranded breaks (131). Besides its interaction with topoisomerase II, etoposide may 
also cause DNA damage by oxidative stress induction (132). Etoposide is known to affect 
spermatogenesis and thus male fertility (240). Studies have shown that etoposide can 
severely affect spermatogenesis, leading to oligospermia and azoospermia, with only half 
of the patients regaining reproductive function (31, 118). Furthermore, etoposide can 
damage DNA synthesis being responsible for an increase of aneuploidies in human 
spermatozoa (120). In vitro studies on etoposide are scarce, only revealing that its 
interaction with topoisomerase II is responsible for the distress of human spermatozoa 
(121). Chemotherapeutic regimens are being constantly improved to attain maximum 
results with the least secondary effects possible. However, most chemotherapeutic 
regimens are still harmful for male fertility (15). Therefore, cytoprotection is an alternative 
to preserve male reproductive capacity during chemotherapy (241). N-acetylcysteine (NAC) 
is a precursor of L-cysteine presenting chemopreventive and antioxidant characteristics 
(189). It is currently being tested for the treatment of several health conditions. The most 
promising results come from its chemopreventive features and antioxidant activity (192, 
193). Studies on its benefits and potential toxicity have demonstrated that this agent is safe 
for clinical use and has several protective effects on cells (195, 196). Furthermore, it has 
been demonstrated that NAC improves human semen parameters (242) and protects rat 
Sertoli cells from damage induced by oxidative stress (154) due to its antioxidant potential. 
In the present study, we assessed the toxic effects of etoposide on human sperm 
and evaluated NAC’s potential as chemoprotecting agent of sperm quality during in vitro 
etoposide exposure. Hence, semen parameters, such as motility, viability and morphology, 
as well as DNA fragmentation and chromatin condensation of sperm exposed to a single 
dose of 25 µg/ml etoposide alone or in combination with 50 µM of NAC were evaluated. 
Furthermore, sperm glycolytic and oxidative profiles were also determined. 
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2. Material and Methods 
 
2.1 Chemicals 
Sperm preparation medium (SPM) was purchased from Medicult Origio (Jyllinge, 
Denmarck). Vectashield antifade medium containing 4′,6-diamidino-2-phenylindole (DAPI) 
was purchased from Vector Laboratories (Burlingame, CA, USA). Protease inhibitor cocktail 
was purchased from Thermo Scientific (Rockford, USA). Etoposide, NAC, sodium 
orthovanadate, Triton X-100, Tris buffer, rabbit anti-DNP and rabbit anti-goat IgG-AP were 
purchased from Sigma (St. Louis, USA). Rabbit nitro-tyrosine antibody was purchased from 
Cell Signaling Tecnology (Massachusetts, USA). Secondary antibody, goat anti-rabbit IgG-
AP was purchased from Santa Cruz Biotechnology (Heidelberg, Germany). All the other 
chemicals were acquired from Merck (Darmstadt, Germany), unless stated otherwise. 
 
 
2.2 Patients selection and semen collection 
Ethical guidelines were followed in the conduct of research, with written informed 
consent having been obtained before the beginning of work. This work did not involve 
human or animal experiments. An approval by an Ethics Committee and the Declaration of 
Helsinki as revised in Tokyo 2004 on human experimentation does not apply to this kind of 
work. Thus, according to the standards of National Law (PMA, Law 32/2006) and Council 
(CNPMA, 2008) criteria on Medically Assisted Procreation, 10 semen samples were used 
after patients had given informed and written consent. Human semen samples were 
obtained from patients performing spermiogram analysis at the private clinic Centro de 
Genética da Reprodução Prof. Alberto Barros (CGR-ABarros). The selected group 
presented a mean age of 33.8±1.2 years. Semen samples were collected by masturbation 
in sterile containers, after a 3 to 5 day period of sexual abstinence. Semen parameters were 
evaluated according to the World Health Organization (WHO) guidelines (243).  Criteria for 
inclusion were: absence of known pathologies and intake of medicines; normal physical 
examination, hormonal profiles and karyotypes; semen analysis without agglutination, 
immature forms, leukocytes and microorganisms, and a sperm concentration ≥ 15x106/ml.  
 
 
2.3 Experimental design 
Semen samples were divided into four groups with different experimental conditions. 
In the control group (CT), samples were incubated with sperm preparation medium (SPM) 
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for a 2h period, in a humidified atmosphere of air containing 5% CO2 at 37ºC. The remaining 
three groups consisted of a 2h incubation period with 25 µg/ml of etoposide (Eto group) or 
50 µM of NAC (NAC group), or the combination of both agents (Eto+NAC group). 
 
 
2.4 Determination of sperm chromatin condensation  
Chromatin condensation was assessed by acidic aniline blue staining.  Sperm 
smears were prepared for each condition and fixed in 3% glutaraldehyde in 0.2M 
phosphate-buffered saline (PBS) solution for 30 min at RT. The slides were then stained 
with 5% aqueous aniline blue mixed with 4% acetic acid (pH = 3.5) for 5 min at RT. Two 
hundred spermatozoa were evaluated and the percentage of dark blue stained sperm 
heads, which indicates immature histone-rich nuclei was calculated.  
 
 
2.5 Determination of sperm DNA fragmentation  
For each sample sperm DNA fragmentation was evaluated by terminal 
deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay using the In Situ Cell 
Death Detection Kit (Roche, Mannheim, Germany), as previously reported (244). Sperm 
were smeared onto adhesion microscope slides, air-dried and fixed for 1h at RT with 4 % 
paraformaldehyde in PBS. Slides were then washed in PBS and permeabilized with a 
solution of 0,1 % Triton-X in 0,1 % sodium citrate for 2min at 4 °C. After washing the slides 
in PBS, they were incubated in a dark moist chamber for 1 h at 37 °C with a 50 μLTUNEL 
mixture. After incubation, slides were washed in PBS and counterstained with Vectashield 
antifade medium containing DAPI. On each slide, at least 200 morphologically normal 
spermatozoa, without any anomalies in the head, mid-piece or tail, were counted in a Leitz 
DMRBE fluorescence microscope (Leica, Wetzlar, Germany). The number of spermatozoa 
emitting green fluorescence (TUNEL-positive) was recorded as a percentage of the total 
counted sperm (DAPI stained).   
 
 
2.6 Determination of oxidative stress markers 
Oxidative stress can be assessed by: cellular protein carbonyl content, a marker for 
protein oxidation; measurement of aldehyde products such as 4-hydroxynonenal (4-HNE), 
an indicator of lipid peroxidation; and quantification of 3-nitrotyrosine (3-NT), an indicator of 
superoxide-dependent peroxynitrite formation. The content of protein carbonyl groups, 4-
Article II 
NAC preserves Human Sperm DNA from Etoposide in vitro 
42 
 
 
 
 
HNE and 3-NT in sperm from the different experimental groups was evaluated using the 
Slot-Blot technique and specific antibodies, as previously reported (210). In brief, total 
proteins were isolated from human spermatozoa using 1% Triton X-100 in 2M Tris-Buffer, 
supplemented with 1% protease inhibitor cocktail and 100 mM sodium orthovanadate 
(phosphatase inhibitor). For carbonyl groups evaluation, protein samples were derivatized 
using 2,4-dinitrophenylhydrazine (DNPH) to obtain 2,4- dinitrophenyl (DNP) according to 
the method previously described by Levine and collaborators (245). The Slot-Blot technique 
was performed using a Hybrid-lot manifold system (Biometra, Göttingen, Germany) and the 
resulting PVDF membranes were incubated overnight at 4ºC with a rabbit anti-DNP 
(1:5000). For lipid peroxidation and protein nitration analysis, protein samples were diluted 
in PBS to a concentration of 3 µg/µL. The resulting membranes were incubated overnight 
at 4ºC with a goat anti-4-HNE antibody (1:5000) and a rabbit nitro-tyrosine antibody 
(1:5000), respectively. Samples were visualized using rabbit antigoat IgG-AP (1:5000) or 
goat anti-rabbit IgG-AP (1:5000), respectively. Membranes were then reacted with ECFTM 
substrate (GE Healthcare, Buckinghamshire, UK) and read using a Bio-Rad Gel Doc XR+ 
(Bio-Rad, Hemel Hempstead, UK). Densities from each band were quantified using the 
Quantity One Software Version 4.6.9 (Bio-Rad, Hemel Hempstead, UK). 
 
 
2.7 Proton Nuclear Magnetic Resonance (1H-NMR)  
The extracellular metabolites from each sample after the incubation period were 
acquired by 1H-NMR, as previously described (246). Sodium fumarate at a final 
concentration of 1 mM was used as an internal reference (6.50 ppm) to quantify the 
following metabolites (multiplet, ppm): H1-α glucose (doublet, 5.22); choline (singlet, 3.18); 
pyruvate (singlet, 2.38); acetate (singlet, 1.9) and lactate (doublet, 1.33 ppm). The relative 
areas of 1H-NMR resonances were quantified using the curve-fitting routine supplied with 
the NUTSpro NMR spectral analysis program (Acorn NMR, Livermore, CA, USA). 
 
 
2.8 Statistical Analysis 
The statistical significance among the experimental groups was assessed by ANOVA, 
followed by Fisher’s LSD. All data are shown as mean ± standard error of mean (SEM) (n 
= 10 for each condition). Statistical analysis was performed using GraphPad Prism 6 
(GraphPad Software Inc., San Diego, CA, USA). All P values < 0.05 were considered 
statistically significant. 
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3. Results 
 
3.1. Patients selection and sperm examination at collection time 
All patients selected for this study were in reproductive age (33.8 ± 1.2 years) and 
presented normal semen pH values. At macroscopic evaluation, the samples presented 
normal colour and smell, liquefied in due time and had regular viscosity. Additionally, no 
leucocytes were found and there was no evidence of agglutination. Furthermore, patients 
had a sample mean volume of 3.8±0.3 ml, a mean number of sperm per ml of 92.2±21.5 
million; a mean percentage of progressive sperm of 46.3±4.9 % and immotile sperm of 
31.1±2.9 %, a teratozoospemia mean index of 1.6± 0.0 %, mean sperm vitality of 74.9± 1.8 
% and mean hypo-osmolarity of 70.3±2.7 % (Table III-1). No significant differences between 
patients were found regarding semen parameters at collection time. 
 
Table III-1. Patients’ data and semen parameters after sample collection. 
Sample Features Mean SEM P value (a) 
Age (years) 33.8 1.19 0.922 
Volume (ml) 3.80 0.306 0.338 
Nº Spermatozoa / ml 92.2 21.5 0.064 
Motility (%) 
Immotile 31.1 2.86 0.137 
Non-Progressive 22.6 2.93 0.135 
Progressive 46.3 4.89 0.727 
Normal morphology (%) 4.75 0.92 0.804 
Teratozoospermia index (%) 1.63 0.0374 0.425 
Vitality (%) 74.9 1.79 0.268 
Hypo osmotic Swelling Test (%) 70.3 2.65 0.303 
 
(a)  P value within each parameter between patients. P value < 0.05 was considered 
significant. 
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3.2. Effects on sperm motility 
Sperm motility is directly related to male fertility potential and is commonly evaluated to 
assess male’s fertilization capacity [27, 28]. Our results showed that the mean percentage 
of progressive motile sperm in the control group was 18.6±3.8 % (Figure III-2A). Similar 
values were found in sperm after exposure to etoposide (19.6±4.5 %). Interestingly, 
incubation of sperm with NAC, alone or in combination with etoposide, did not significantly 
alter sperm progressive motility though it was 22.4±5.9 % and 22.7±6.0 %, respectively. 
Our results also showed that non-progressive motility was not altered in any of the groups 
in comparison to the control group (data not shown). Likewise our results revealed that the 
mean percentage of immotile sperm, which was 59.6±6.5 % in the control group, was not 
significantly altered by exposure to etoposide (61.6±5.6 %), NAC (59.2± 6.8 %) and the 
combination of both agents (60.3±7.5 %) (Figure III-2B). 
 
 
3.3. Effects on sperm morphology 
It is well-established an association between the percentage of morphologically normal 
sperm and pregnancy rates [29, 30]. Therefore, sperm morphology evaluation is useful for 
the assessment of male fertility potential. Our results showed that the mean percentage of 
normal sperm was 4.8±0.9 % in the control group and was not significantly altered after 
exposure to etoposide (4.8±0.9 %), NAC (4.7±0.9 %) and the combination of both agents 
(4.7±1.0 %) (Figure III-2C). Our results also showed that the mean percentage of sperm 
with head defects in the control group was 94.2±1.1 %. This percentage was not altered in 
sperm incubated with etoposide (95.5±3.3 %), NAC (95.9±2.3 %) or when both agents were 
in combination (94.0±3.1 %) (Figure III-2C). No other significant alterations in specific 
defects, including mid-piece, tail and cytoplasmic excess, were observed in human sperm 
after incubation with etoposide or/and NAC. 
 
 
3.4. Effects on sperm membrane integrity 
Sperm viability is clinically important since only viable sperm are able to successfully 
fertilize the oocyte. It can be evaluated by assessing sperm flagellum integrity by the hypo-
osmotic swelling (HOS) test [31]. Reactive sperm to the HOS test represent viable sperm 
with intact membranes. Our results showed that the mean percentage of reactive sperm in 
the control group was 47.1±2.7 % and was not significantly altered after exposure to 
etoposide (52.4±3.4 %), NAC (46.3±2.7 %) and the combination of both agents (45.7±3.8 
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%) (Figure III-2D). Interestingly, the exposure to NAC and the combination of both drugs 
reduced sperm viability in relation to etoposide (p=0.04 and p=0.03, respectively) but not to 
controls (Figure III-2D). 
 
 
3.5. Effects on sperm chromatin condensation and DNA fragmentation 
Sperm chromatin is a highly organized and condensed structure, with no distinguishable 
chromosomes visible. These characteristics protect sperm genetic integrity and facilitate 
oocyte fertilization [32]. Our results showed that the mean percentage of sperm with 
immature chromatin condensation was 17.2±1.2 % in the control group. Noticeably, 
exposure to etoposide significantly increased the percentage of sperm with immature 
chromatin condensation (26.6±2.8 %) in relation to the control (p=0.02) (Figure III-2E). 
Sperm treated with NAC (17.5±3.1 %) or Eto+NAC (15.8±1.9 %) presented values similar 
to the control group, but significantly lower than etoposide group (p=0.04 and p<0.0001, 
respectively) (Figure III-2E).  
Sperm DNA fragmentation is clinically relevant to assess male reproductive capacity 
[33]. Our results showed that the mean percentage of sperm with fragmented DNA in the 
control group was 10.8±2.1 % (Figure III-2F). However, after exposure to etoposide, sperm 
DNA fragmentation highly increased (15.9±0.7 %) in relation to control group (p=0.019). 
Sperm treated with NAC (10.3±1.6 %) or Eto+NAC (10.6±1.6 %) presented values similar 
to the control group, but significantly lower than etoposido group (p=0.02 and p=0.02, 
respectively) (Figure III-2F).  
Notably, the addition of NAC to etoposide-exposed sperm was able to protect sperm 
DNA integrity as results were close to non-exposed sperm. 
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3.6. Effects on sperm oxidative stress 
Oxidative stress plays a key role in male fertility, being a possible cause for defective 
sperm, decreased sperm motility and loss of reproductive potential (247, 248). Protein 
carbonyl and nitration, as well as lipid peroxidation, are commonly used markers to evaluate 
oxidative stress damage. While evaluating protein nitration it was observed that 
interestingly, the exposure of human sperm to etoposide did not increase nitration levels, 
presenting values close to those of the control group (1.0±0.1 fold variation to control) 
(Figure III-3A). However, sperm incubated with NAC or both Eto+NAC displayed 
significantly higher levels of nitration than those of sperm exposed to etoposide alone 
[1.1±0.1 fold variation to control (p=0.04) and 1.2±0.1 fold variation to control (p=0.02), 
respectively] (Figure III-3A). Furthermore, our results showed that carbonyl groups content 
was similar in all groups in relation to the control and no significant differences were 
observed (Figure III-3B). Similarly, the lipid peroxidation levels detected in sperm after 
incubation with etoposide or/and NAC were close to those detected in the control and no 
significant differences were noted (Figure III-3C). 
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Figure III-3. Effect of exposure of human sperm to etoposide or/and NAC on oxidative stress 
markers. Protein nitration levels (panel A); protein carbonyl levels (panel B) and lipid peroxidation 
(panel C) were measured in human sperm after exposure to 25 µg/ml of etoposide (Eto), 50 µM of 
NAC (NAC) and both drugs in combination (Eto+NAC). Results are expressed in relation to the 
control group (Fold variation to control). Statistical significance was assessed by RM one-way 
ANOVA, followed by Fisher’s LSD. Results are expressed as mean ± SEM (n=10 for each condition). 
Significantly different results (p< 0.05) are indicated as: a, relative to Eto. 
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3.7. Effects on sperm metabolism 
Sperm metabolism and nutritional status play a crucial role in the overall reproductive 
capacity, and alterations in the metabolic profile of sperm are related to male factor infertility 
(249). The sperm preparation medium presents high amounts of glucose, which is essential 
for sperm capacitation and fertilization, being one of the preferential substances used by 
sperm for ATP production (250). As expected, our results showed that human sperm highly 
consumed glucose. In the control group glucose consumption was 32.0±5.2 pmol/106 sperm 
(Figure III-4A). No significant alterations were observed after incubation of human sperm 
with any of the agents tested. Nonetheless, sperm incubated with both drugs in combination 
revealed a non-significant increase of 1.5 fold in glucose consumption levels (Figure III-4A).  
Pyruvate is other crucial substrate for sperm metabolism being responsible for the 
enhancement of glycolytic ATP production, sperm motility, capacitation and overall fertility 
status (251). Our results showed that pyruvate consumption was 10.6±2.0 pmol/106 sperm 
in the control group (Figure III-4B). Exposure of human sperm to etoposide or/and NAC did 
not alter pyruvate consumption in comparison to the control. Nevertheless, sperm incubated 
with Eto+NAC revealed a non-significant increase of 1.6 fold in pyruvate consumption levels 
(Figure III-4B). Although lactate was not present in sperm preparation medium it was 
accumulated in all groups. In the control group lactate production by human sperm was 
11.2±1.0 pmol/106 sperm (Figure III-4C). Neither the exposure of sperm to etoposide, nor 
the exposure to NAC, or both drugs in combination altered lactate production (Figure III-
4C).  
Acetate is an important metabolite in fatty acids and cholesterol synthesis pathways 
(252). Our results showed that acetate production by human sperm was 0.001±0.001 
pmol/106 sperm in the control group (Figure III-5A). After incubation with etoposide, NAC 
and a combination of both agents there were no significant differences in acetate production 
(Figure III-5A).  
Choline is an important nutrient for sperm physiology, being a pivotal factor for sperm 
maturation and fertilization capacity (253). Furthermore, this nutrient is essential for sperm 
motility (254). Choline accumulation was 0.4±0.1 pmol/106 sperm in the control group 
(Figure III-5B). Similar levels were obtained in sperm incubated with etoposide (0.4±0.1 
pmol/106 sperm). Interestingly, exposure of human sperm to NAC displayed a significant 
increase (p=0.04) in choline accumulation levels, 1.1±0.4 pmol/106 sperm, in relation to 
control group, etoposide and Eto+NAC groups. Notably, sperm exposed to both agents had 
the lowest levels of choline accumulation 0.1±0.1 pmol/106 sperm, a significant decrease in 
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relation to the sperm exposed to NAC (p=0.004) but not to control or etoposide groups 
(Figure III-5B). 
 
Figure III-4. Effect of exposure of human sperm to etoposide or/and NAC on glucose 
metabolism. Glucose consumption (panel A); pyruvate consumption (panel B) and lactate 
production (panel C) were measured in human sperm before (CT) and after exposure to 25 µg/ml of 
etoposide (Eto), 50 µM of NAC (NAC) and both drugs in combination (Eto+NAC). Statistical 
significance was assessed by RM one-way ANOVA, followed by Fisher’s LSD. Results are 
expressed as mean ± SEM (n = 10 for each condition).  
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Figure III-5. Effect of exposure of human sperm etoposide or/and NAC on acetate and choline 
production. Acetate (panel A) and choline (panel B) production measured in human sperm before 
(CT) and after exposure to 25 µg/ml of etoposide (Eto), 50 µM of NAC (NAC) and both drugs in 
combination (Eto+NAC). Statistical significance was assessed by RM one-way ANOVA, followed by 
Fisher’s LSD. Results are expressed as mean ± SEM (n = 10 for each condition). Significantly 
different results (p< 0.05) are indicated as: a, relative to control (CT); b, relative to Eto; c, relative to 
NAC. 
 
.  
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4. Discussion 
Etoposide is a chemotherapeutic drug regularly used as a first-line agent in the 
treatment of numerous neoplasia common in patients of reproductive age (128). It is a 
phase-specific, cytotoxic drug that inhibits DNA synthesis by forming a complex between 
topoisomerase II and DNA (131). Most chemotherapeutics are known as gonadotoxic 
though, most of their adverse effects on male reproduction are difficult to predict (31). In an 
effort to preserve healthy cells from chemotherapy-induced damages, various 
cytoprotective agents have been tested (151). NAC is a derivative of the amino acid L-
cysteine (189) and its administration as supplement against several diseases is being 
tested. Some encouraging results have been reported due to its chemopreventive features 
and antioxidant activity (192, 193). Thus, we aimed to evaluate NAC’s ability to preserve 
human sperm from the in vitro damaging effects induced by etoposide.  
Our results show that in vitro exposure of human sperm to a pharmacological 
concentration (25 µg/ml) of etoposide does not significantly alter their motility, morphology 
and membrane integrity. It was previously reported that exposure to etoposide in vitro 
resulted in decreased sperm quality and viability (128). Accordingly, the evaluation of 
patients treated with etoposide-based therapies revealed a decrease in the overall 
spermatic quality after treatment (255). Moreover, patients treated with 100 mg/m2 of 
etoposide for a 5 day period presented a low percentage of morphologically normal sperm 
(118). Although our results show that a 2 h exposure to etoposide is insufficient to 
significantly alter sperm motility, morphology and viability. The incubation of human sperm 
with NAC does not affect sperm motility and morphology, but reduces cell viability when 
compared to etoposide. Several studies in other cellular types have reported that NAC can 
have a pro-oxidant activity under certain conditions (256, 257). Pro-oxidant environments 
have been associated with a decrease in the overall spermatic quality, particularly cell 
viability (247), which would explain the NAC-induced deleterious effects on sperm viability 
found in our study.  
In addition to sperm motility, viability and morphology, it is crucial to evaluate DNA 
integrity when assessing the overall sperm quality (258). Indeed, it is essential for male 
fertility to produce sperm with highly condensed and preserved DNA (259). A reduction in 
sperm quality after chemotherapeutic treatment is generally attributed to DNA damage 
(260). Our results show that a 2 h exposure of human sperm to etoposide is responsible for 
an increase in the percentage of sperm with immature chromatin condensation. 
Furthermore, etoposide is responsible for a high increase in DNA fragmentation levels and 
therefore, in the percentage of TUNEL positive sperm. Studies conducted in mice germ 
cells in vitro have showed that exposure to etoposide (5 mM for 6 h) results in vast DNA 
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damage and chromatin modifications (261). Moreover, it has been previously reported that 
treatment with etoposide therapeutic dosages (40-80 mg/kg) was responsible for an 
increase in the density of TUNEL positive cells in rats (240), and a high increase in sperm 
chromosomal aberrations (260) and DNA mutations (262) in mice. Our results are 
concomitant with these previous studies since they show that a 2 h exposure to etoposide 
induces DNA damage in sperm. Notably, sperm exposed to a combination of etoposide and 
NAC presented levels of immature chromatin condensation and DNA fragmentation similar 
to the control group, and lower than those observed in etoposide-exposed sperm, thus 
illustrating that NAC preserves DNA integrity of human sperm exposed to etoposide. Others 
have shown that NAC inhibits spontaneous and induced mutations, preventing DNA 
damage (263, 264). Studies have also reported that NAC has solid DNA protective effects, 
either by acting in the extracellular environment or by replenishing cellular antioxidant 
mechanisms (265). A study conducted by Lopes and colleagues has reported that the 
addition of NAC (0.1 mM) to sperm reduces DNA fragmentation induced by oxidative stress 
(266). The same was observed in other human cellular types, where 500 µM of NAC 
protected cells from oxidative stress-induced toxicity (267). Thus, our results show that 2 h 
exposure of human sperm to etoposide causes chromatin and DNA damage. The exposure 
to NAC alone does not significantly affect sperm DNA integrity. Nonetheless, the addition 
of NAC to etoposide shields human sperm DNA, particularly chromatin condensation and 
DNA fragmentation levels.   
It has been hypothesised that etoposide induces DNA damage by ROS formation 
and the consequent induction of oxidative stress (132). Our results show that 2 h exposure 
of human sperm to etoposide does not alter the oxidative profile of these cells in relation to 
protein nitration and carbonylation and lipid peroxidation. An in vitro study with rat 
thymocytes exposed to 10 µM of etoposide for a 4 h period reported apoptosis induction 
probably due to hydroxyl radical formation (268). Others have also reported hydroxyl radical 
production by etoposide, which caused DNA nicking (269). Although these results are not 
in agreement with our findings, it should be noted that our experiment was performed in a 
2 h exposure. Therefore, our results provide evidence that 2 h exposure of human sperm 
to etoposide does not induce major cellular oxidative damages. Our results also revealed 
that exposure of sperm to NAC alone does not alter the oxidative profile of sperm in relation 
to protein carbonylation and lipid peroxidation. Interestingly, human sperm incubated with 
NAC alone or in combination with etoposide displayed an increase in protein nitration. 
These findings are in agreement with the reduction in sperm viability observed after 
exposure to NAC and etoposide plus NAC. Several studies reported the antioxidant 
properties of NAC as the main mechanism for sperm protection and DNA fragmentation 
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reduction (242, 266). It was also reported that incubation of human semen with 1 mg/ml of 
NAC at room temperature significantly decreased ROS levels after 20 min (270). 
Nonetheless, this reduction was dose-dependent and greater in groups with initial higher 
ROS production. There is some controversy on the antioxidant and pro-oxidant properties 
of NAC, which may depend on the dose and exposure time. For instance, an in vivo study 
with mice has shown that NAC exerts a strong antioxidant defense in cells with increased 
nitrative stress (271). However, studies in other cellular types reported that NAC can have 
a pro-oxidant activity, generating hydrogen peroxide and increasing the secretion of nitric 
oxide and cellular nitrotyrosine (256, 257). Thus, our results suggest that, in our 
experimental conditions, NAC has pro-oxidant activity, increasing nitrotyrosine levels and 
reducing sperm viability in relation to sperm exposed to etoposide alone. It has been 
previously reported that etoposide acts by inhibiting topoisomerase II, an enzyme 
responsible for relaxing supercoiled DNA, forming a stable complex between 
topoisomerase II and DNA, which directly results in DNA strand break, cell cycle blockage 
and finally cellular death (131). Hence, our results provide evidence that etoposide directly 
affects sperm chromatin condensation and DNA fragmentation without oxidative stress-
mediated mechanisms. 
Sperm cells metabolism is essential to obtain the required energy for sperm regular 
functions, such as motility, being glycolysis the preferential pathway (249). Our results show 
that human sperm glucose consumption was maintained after exposure to etoposide. 
Moreover, sperm exposed to NAC alone or in combination with etoposide showed no 
significant alteration in glucose and pyruvate uptake, and lactate and acetate production. 
These results illustrate that the glycolytic profile of human sperm is not altered by 2 h 
exposure to etoposide, NAC or the combination of both drugs. Nevertheless, recent studies 
have reported that high glucose levels in culture medium protect cells from the deleterious 
effects of etoposide (272). These findings are in agreement with our results that show no 
decrease in sperm viability and motility after 2 h exposure to etoposide. To the best of our 
knowledge this is the first report on the effects of etoposide or/and NAC on glucose 
metabolism. Overall, our results provide evidence that neither etoposide nor NAC affect 
human sperm glycolytic profile. Interestingly, choline metabolism is associated with 
regulation of sperm membrane structure and fluidity, being crucial for sperm cells function 
(253). In fact, male choline dehydrogenase knockout mice (Chdh-/-) are infertile (254). Our 
results show that exposure of human sperm to NAC alone is responsible for an increase in 
extracellular choline accumulation in relation to all groups. These results suggest that 
deregulated choline metabolism may be associated with the observed decrease in sperm 
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viability after exposure to NAC. Further studies are needed to unveil the relevance of choline 
metabolism and NAC to human sperm. 
In conclusion, although 2 h exposure to etoposide does not affect sperm viability, it 
induces severe chromatin alterations and DNA damage to human sperm. These alterations 
may compromise male fertility and are potentially transmittable to the next generation (273). 
The addition of NAC to etoposide sperm exposure protected cellular chromatin integrity and 
reduced DNA fragmentation. Thus, it acts as a cytoprotector agent, shielding human sperm 
DNA from etoposide-induced damages. A 2 h exposure of human sperm to etoposide does 
not induce cellular oxidative damages nor glycolytic profile alterations, providing evidence 
that etoposide directly affects sperm DNA. NAC’s ability to preserve human sperm from 
DNA damages induced after a 2 h exposure to etoposide may be of clinical relevance, as 
the majority of patients undergoing chemotherapy fail to collect semen samples prior to the 
initiation of treatment (20). NAC presents indeed great advantages as it is an inexpensive 
drug, already approved for safe human use, with minimal adverse effects. Thus, the integrity 
of the collected sperm after treatment initiation could be more easily preserved with the 
addition of NAC, guaranteeing that the majority of viable cells would have their DNA integrity 
preserved. Thus assuring that the future use of these patients’ cryopreserved sperm in 
assisted reproductive techniques would not be compromised. Further studies are needed 
to effectively assess NAC’s beneficial effects on human sperm during chemotherapy. 
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Final Remarks 
Cancer treatment has been improving and survival rates are at their highest 
percentage ever. Chemotherapy secondary effects on male fertility are varied and it is 
difficult to predict the individual potential risk for persistent infertility. Thus, several fertility 
preservation options are being studied and must be debated with patients.  
Our study on the damaging effects of etoposide on human spermatozoa and NAC’s 
ability to preserve these cells from such damages provide evidence that the addition of NAC 
to sperm exposed to etoposide protects cellular chromatin integrity and reduces DNA 
fragmentation. Overall, our results show that the mechanism behind etoposide cytotoxic 
action relies on its direct interaction with DNA, not causing oxidative damages nor altering 
the glycolytic profile of human sperm. Furthermore, short-term exposure to etoposide does 
not affect sperm vitality, motility or morphology. Nonetheless, it induces severe chromatin 
alterations and DNA fragmentation, severely compromising male fertility.  
According to our results, NAC addition to sperm exposed to etoposide protects sperm 
chromatin integrity and reduces DNA fragmentation. These findings suggest that NAC acts 
as a cytoprotector agent, shielding human sperm DNA from etoposide-induced damages. 
However, the mechanism behind NAC’s ability to preserve human sperm from DNA 
damages induced after a short-term exposure to etoposide does not seem to rely on its 
antioxidant properties.  
As the majority of patients initiating chemotherapy fails to collect semen samples prior 
to the beginning of treatment, NAC’s ability to preserve sperm DNA is of clinical relevance. 
Indeed, NAC presents numerous advantages as it is an inexpensive drug, has already been 
approved for human use and has minimal side effects. Hence, DNA integrity of sperm 
collected after treatment initiation could be preserved with the addition of NAC, assuring the 
majority of viable spermatozoa would be suitable for future use in Medically Assisted 
Reproduction.  
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Future Perspectives 
Although our results on NAC’s aptitude as a protector agent of human spermatozoa 
against etoposide-induced damages are promising, supplementary research must be 
conducted to attest the mechanism involved in NAC ability to protect DNA. Moreover, it 
would be useful to measure cellular glutathione levels after etoposide and NAC 
administration to the cellular medium, and with both agents in combination, to validate our 
results that oxidative stress does not play a role in etoposide cytotoxicity mechanism. 
Likewise, further studies are needed to assess NAC’s effects on human spermatozoa during 
long-term chemotherapeutic treatment.  
Although our results on NAC’s use against etoposide-induced damages to mature 
spermatozoa are promising, there are no certainties on its competence against other types 
of chemotherapeutic drugs. Therefore, it would be interesting to assess its cytoprotector 
abilities against other agents. Furthermore, as antioxidants have stronger effects on cells 
already under stress, it would be of value to administer NAC to cells that have been 
previously exposed to chemotherapeutics. Although this would not have direct benefits on 
spermatozoa already produced in the first chemotherapeutic regimen, it could be beneficial 
to preserve spermatogonia and assure the future maintenance of spermatogenesis. 
Additionally, as antioxidants alone can have pro-oxidant effects, and in combination 
can have strong antioxidant activities, it would be interesting to expose cells to NAC in 
combination with other powerful antioxidants and assess their ability to fully preserve 
spermatozoa, already produced at the beginning of chemotherapy, and other cells of the 
spermatogenic line, assuring the maintenance of spermatogenesis. 
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I. Material and Methods 
 
1. Ethical considerations 
Ethical guidelines were followed in the conduct of research, with written informed 
consent having been obtained before the beginning of work. This work did not involve 
human or animal experiments. An approval by an Ethics Committee and the Declaration of 
Helsinki as revised in Tokyo 2004 on human experimentation does not apply to this kind of 
work. Thus, according to the standards of National Law (PMA, Law 32/2006) and Council 
(CNPMA, 2008) criteria on Medically Assisted Procreation. Human semen samples were 
obtained from patients performing spermiogram analysis at the private clinic Centro de 
Genética da Reprodução Prof. Alberto Barros (CGR-ABarros) after they had given informed 
and written consent. 
 
2. Patient and sample selection 
The semen samples used in this study were acquired from 10 individuals that went 
for semen analysis at CGR between October and November 2014. In order to be selected 
for this study, samples had to meet the following inclusion criteria: 
 
 No known diseases; 
 No prolonged pharmacological therapy; 
 Normal physical exam ; 
 Normal karyotype, with no micro deletions of the Y chromosome;  
 Normal hormonal profile; 
 Semen analysis presenting no agglutination, immature forms, leukocytes or 
microorganisms and a sperm concentration ≥ 15x106/ml. 
 
3. Experimental design 
In this study, each semen sample selected by the above criteria was divided into four 
experimental groups subjected to different conditions (Figure VII-1). After removal of the 
seminal fluid semen parameters were evaluated at CGR and a portion from samples 
meeting our criteria was transferred for research. Each sample was diluted in sperm 
preparation medium (SPM; Origio, Jyllinge, Denmark), supplemented or not with etoposide 
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(Sigma, St. Louis, MO, USA), NAC (Sigma) or both agents in combination, and incubated 
for a 2h period, in a humidified atmosphere of air containing 5% CO2 at 37ºC. Several NAC 
concentrations were evaluated and analysed in order to maximize results without damaging 
the spermatozoa (Annexes II). Each sample was divided into the following experimental 
conditions: 
 
 Control group (CT group): samples were incubated in SPM containing a 
0.05% dimethyl sulfoxide (DMSO; Merck, Darmstadt, Germany) 
concentration; 
 Etoposide group (Eto group): samples were incubated in SPM with 0.05% 
DMSO in combination with a pharmacologically relevant concentration of 
etoposide (25 µg/ml); 
 N-acetylcysteine group (NAC group): samples were incubated in SPM with 
0.05% DMSO in combination with 50 µM of NAC; 
 Etoposide and N-acetylcysteine group (Eto+NAC group): samples were 
incubated in SPM with 0.05% DMSO in combination with 25 µg/ml of 
etoposide and 50 µM of NAC. 
After the incubation period we evaluated spermatozoa motility, hipoosmolarity, 
morphology, DNA fragmentation and chromatin condensation. The remaining sample 
volume was then centrifuged at 670 Xg and both supernatant and pellet stored separately 
Figure VII-1. Schematic representation of the experimental groups. Each sample was 
analysed at the end of the incubation period. Samples were incubated in four different 
conditions. SPM corresponded to the control group and the three remaining groups were of 
etoposide, NAC, or both agents in combination. 
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at -20°C for oxidative damage analysis and for extracellular metabolites determination, 
respectively. 
 
 
4. Semen analysis (Spermiogram) 
Semen samples were obtained by masturbation into sterile plastic containers after a 
3 to 5 day period of sexual abstinence. Immediately after collection, samples were placed 
at 37 °C while the semen liquefied. The macroscopic examination, which includes 
liquefaction, viscosity, appearance, volume and pH, as well as the microscopic examination 
were performed according to WHO guidelines 2010 (243). The normal value range for 
sample parameters and protocols for the macroscopic exam can be found in Annexes III 
and IV, respectively. 
 
4.1. Macroscopic examination 
 
4.1.1. Liquefaction 
Immediately after ejaculation into the sterilized container, semen is 
typically a semi-solid coagulated mass. Within a few minutes at room 
temperature (RT), or in a CO2 incubator at 37ºC, semen regularly begins to 
liquefy. When the semen sample is liquefied it becomes homogeneous and 
watery. The complete sample, if normal, generally liquefies within 15 to 30 
min at RT, not taking longer than an hour. 
 
4.1.2. Viscosity 
After liquefaction, the viscosity of the sample is evaluated by gentle 
aspiration using a pipette, allowing sperm to fall by gravity and observing the length 
of the thread. Viscosity is considered normal when the semen lefts the pipette into 
small droplets. If the sample dropped in threads of more than 2 cm long it is 
considered abnormal. High viscosity may interfere with the evaluation of sperm 
parameters such as motility and concentration. 
 
4.1.3. Appearance of the ejaculate 
Samples appearance at RT is observed after the liquefaction process is 
complete. Samples are considered normal when the liquefied semen has a 
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homogeneous, gray-opalescent appearance. Samples may however look less 
opaque when sperm concentration is very low. Color may also be different. Samples 
with a red-brown color indicate the presence of red blood cells in the ejaculate 
(haemospermia), and yellow samples are characteristic of man with jaundice, taking 
certain vitamins or drugs, or the presence of infections.  
 
4.1.4. Smell 
Normal semen samples have a characteristic odor regarded as sui generis. 
Abnormal samples may not have smell or present a displeasing fetid smell. 
 
4.1.5. Volume 
Total volume of ejaculate is mostly constituted by fluids from the seminal 
vesicles and prostate gland, in addition to a small amount from the bulbourethral 
glands and the epididymis. The volume is directly measured using a graduated 
device. Low semen volume is characteristic of obstruction of the ejaculatory duct, 
congenital bilateral absence of the vas deferens, sample collection problems with 
loss of a fraction of the ejaculate, partial retrograde ejaculation or androgen 
deficiency. High volumes point to exudation in cases of active inflammation of the 
accessory glands. 
 
4.1.6. pH 
Semen pH reveals the balance between the alkaline secretion of seminal 
vesicles (fructose, citrate, inositol, prostaglandins) and the acidic secretion of the 
prostate gland (citric acid, acid phosphatase, amylase and fibrolisine). The pH is 
measured after liquefaction and a sample is considered normal when the pH value 
is at least 7.2 (lower threshold value). 
 
 
4.2. Microscopic examination 
 
4.2.1. Sperm concentration 
Concentration is determined in Neubauer chamber after sample fixation with 
a solution that incites an osmotic shock. The lower reference limit for spermatozoa 
concentration is 15x106/ ml (243). After, samples sre diluted in distilled H2O 
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according WHO recommendations (Table VII-1), they are then added to a Neubauer 
chamber, placed in a humidified container for 10 to 15 min and counted. 
 
Table VII-1 | Sperm sample dilution values. 
Number spermatozoa / 
microscopic field (400X) 
Dilution 
factor 
Semen 
(µl) 
Distilled H2O 
(µl) 
<3 1:2 50 50 
3-10 1:5 50 200 
10-25 1:10 50 450 
25-100 1:20 50 950 
>100 1:50 50 2450 
 
4.2.2. Sperm motility 
Sperm motility should be assessed as soon as possible after sample 
liquefaction and is closely related to male fertility and pregnancy rates (243). 
Sperm motility is evaluated and graded, differentiating spermatozoa with 
progressive or non-progressive motility from those that are immotile, as follows: 
 
 Progressive motility (PR): spermatozoa actively moving 
independently of the speed.   
 Non-progressive motility (NP): all other patterns of motility with an 
absence of progression, e.g. when only a flagella beat can be 
observed. 
 Immobility (IM): absent of movement. 
To evaluate sperm motility, semen samples are carefully homogenised and 
wet preparations are made onto slides previously heated on a stage warmer to a 
temperature of 37°C. Slides are then examined with an optical microscope at a total 
magnification of 400x. Motility is evaluated for at least 200 spermatozoa with the aid 
of a laboratory counter (Digisystem Laboratory Instruments Inc., Taipei, China). In 
each field PR spermatozoa are initially counted, then NP and finally IM spermatozoa. 
Results are then expressed in the percentage of each category per slide.  
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4.2.3. Sperm Vitality: Hypo-osmotic assay 
Sperm vitality is estimated by assessing the membrane integrity of the 
spermatozoa. Sperm vitality can be assessed by evaluating the integrity of the 
flagellum. The hypo-osmotic swelling (HOS) test presumes that only live cells, those 
with intact membranes, will swell when incubated in hypotonic solutions.  Therefore, 
live cells are distinguishable by the swelling of the sperm tail. Swollen spermatozoa 
are identified by changes in the shape of the cell, as indicated by coiling of the tail 
(Figure VII-2). The HOS test is considered within the normal range when the 
percentage of reactive spermatozoa is above 58% (243). 
To evaluate sperm vitality through the HOS assay, 10 µl of each semen 
sample are incubated at 37°C for 30 minutes in 100 µl of the swelling solution (0.735 
g of sodium citrate di-hydrate (Merck) with 1.351 g of D-fructose (Sigma) in 100 ml 
of purified water). A 10 µl aliquot of the sample is then transferred onto a clean slide, 
cover with a coverslip and examined with an optic microscope at a 400X 
magnification (Figure VII-3). Two hundred spermatozoa are evaluated as un-swollen 
(dead) or swollen (vital) and results are presented as percentages. 
 
 
Figure VII-2. Hypo-osmotic assay. Schematic representation of usual morphological 
changes in human spermatozoa subjected to hypo-osmotic swelling test. Spermatozoon (a) 
represents a dead spermatozoa with no reaction of the tail. Spermatozoa (b) to (g) represent 
vital cell with coiling of the tail, represented as grey areas. Adapted from WHO, 2010. 
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Figure VII-3. Photo of human spermatozoa 
subjected to hypo-osmotic swelling test. 
When normal spermatozoa are incubated with a 
hypotonic solution the tail swells, curling on itself. 
This phenomena can be observed in an optic 
microscope. Spermatozoa A to D represent live 
spermatozoa with different forms of tail coiling. 
Total magnification: ×400. 
 
 
4.2.4. Sperm morphology 
Assessment of sperm morphology is associated with various complications 
related to lack of objectivity, variable morphology, variation in interpretation or poor 
performance in external quality-control assessments. For a spermatozoon to be 
considered normal, both its head and tail must be normal. All borderline forms should 
be considered abnormal. Human semen samples contain spermatozoa with different 
kinds of malformations. A higher percentage of abnormal spermatozoa is 
characteristic of a defective spermatogenesis and some epididymal pathologies, 
and is normally a sign of decreased fertilizing potential. Morphological defects have 
also been associated with increased DNA fragmentation (274), an increased 
incidence of structural chromosomal aberrations (275), immature chromatin 
condensation (276) and aneuploidy (277).  
The following categories of spermatozoa morphological defects should be 
noted (Figure VII-4): 
 Head defects (HD): large or small, tapered, pyriform, round, 
amorphous, vacuolated, small or large acrosome areas, double 
heads, or any combination of these. 
 Neck and mid-piece defects (ND): asymmetrical insertion of the mid-
piece into the head, thick or irregular, sharply bent, abnormally thin, 
or any combination of these. 
 Tail defects (TD): short, multiple, broken, smooth hairpin bends, 
sharply angulated bends, of irregular width, coiled, or any 
combination of these. 
 Excess residual cytoplasm (ERC): this is associated with abnormal 
spermatozoa produced from a defective spermatogenesis. .  
 
 
A 
B 
C 
D 
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Staining procedure: 
1. A smear for each sample is prepared on a slide and air-dried; 
2. The smear is then fixated with 96% ethanol (Merck) for 15 min at RT; 
3. After fixation samples are stained as follows: 
i. Ethanol 50% for 2 to 3 min; 
ii. 10 immersion in purified H2O; 
iii. Harris’s haematoxylin (Merck) for 8 min; 
iv. Running tap H2O for 5 min; 
v. 4 to 8 immersions in 37% acidic ethanol (1ml of hydrochloric 
acid (Merck) at  in 100 ml of ethanol and 100 ml of distilled 
H2O); 
vi. Running tap H2O for 5 min; 
vii. 1 immersion in purified H2O; 
viii. 10 immersions for each increasing concentration of ethanol 
(50, 70, 80 and 96%); 
ix. Orange G-6 (Merck) for 4 min; 
x. 10 immersions in 96% ethanol (2x); 
xi. EA-50 (Sigma) for 5 min; 
xii. 10 immersions in 96% ethanol (3x) 
4. After the staining process is completed, slides are observed in the 
optical microscope with the immersion objective 100x (1000x total 
magnification);  
5. 200 spermatozoa are counted with the aid of a laboratory counter.  
6. Spermatozoa are classified as normal or abnormal, with different 
defects of the head, mid-piece, tail or cytoplasmic excess). 
7. Results are expressed as the percentage of spermatozoa in each 
category. 
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5. Sperm DNA integrity Analysis  
Several methods have been used to test the normality of sperm chromatin and DNA. 
Methods include those based on dyes that bind to histones (aniline blue) and assessment 
of DNA strand breaks, such as terminal deoxynucleotidyl transferase (TdT)-mediated 
deoxyuridine triphosphate (dUTP)-nick-end labelling (TUNEL), respectively. 
 
5.1. Determination of chromatin condensation  
Sperm chromatin condensation is assessed by acidic aniline blue staining 
(AB; Merck). Sperm smears are prepared onto adhesive microscope slides and fixed 
in 3% glutaraldehyde (Merck) in 0.2M PBS (potassium phosphate, sodium chloride, 
sodium phosphate; Merck) solution for 30 min at RT. Slides are then stained with 
5% aqueous aniline blue solution mixed with 4% acetic acid pH 3.5 (Merck) for 5 
min at RT. After the staining procedure is completed, 200 morphologically normal 
spermatozoa are evaluated in a bright field microscope (Olympus CX21, Melville, 
NY) with the immersion objective 100X at a total magnification of 1000X (Figure VII-
5). Results are expressed as the percentage of dark blue stained spermatozoa 
Figure VII-4. Schematic representation of abnormal forms of human spermatozoa. Human 
semen samples can present a significant number of spermatozoa with head, neck and tail 
defects, as well as excess of residual cytoplasm. Adapted from WHO, 2010. 
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(indicator of immature histone-rich nuclei). Samples with more than 20% of the 
spermatozoa showing dark blue staining are considered abnormal. 
 
5.2. Determination of sperm DNA fragmentation  
For each sample sperm DNA fragmentation is evaluated by the TUNEL assay at the 
end of each condition, using the In Situ Cell Death Detection Kit (Roche, Mannheim, 
Germany). Sperm smears are prepared onto adhesive microscope slides and fixed in a 4 
% paraformaldehyde (Merck) in PBS solution for 1h at RT. Slides were then washed in PBS 
and permeabilized with a 0,1 % Triton-X in 0,1 % sodium citrate (Sigma)  solution for 2 min 
at 4 °C. Once again slides were washed in PBS and then incubated for 1 h in a dark humid 
chamber at 37 ºC with 50 µl of TUNEL mixture. After counterstaining with Vectashield 
antifade medium containing 4′6-diamidino-2-phenylindole (DAPI; Vector Laboratories, 
Burlingame, CA, USA), 200 morphologically normal spermatozoa were evaluated in a Leitz 
DMRBE fluorescence microscope (Leica, Wetzlar, Germany) (Figure VII-6). The number of 
permatozoa emitting green fluorescence (TUNEL-positive) was recorded as a percentage 
of the total number of sperm counted (DAPI stained). 
 
 
Figure VII-5. Chromatin condensation 
analyses of human spermatozoa by acid-
aniline blue staining. Spermatozoon positive for 
the acid-aniline blue coloration (A) displays
immature chromatin condensation. 
Spermatozoon negative for the acid-aniline blue 
coloration (B) presents normal chromatin 
condensation. 
 
Figure VII-6. DNA fragmentation analyses of 
human spermatozoa by dUTP nick-end 
labelling (TUNEL) assay. In image I 
spermatozoa are stained in blue by DAPI. In 
image II spermatozoa with fragmented DNA are 
stained in green with FITC. In image III, the 
merge of I and II, reveals the fragmented 
spermatozoa in the total of spermatozoa 
observed. 
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6. Sperm protein extraction 
To analyse sperm proteome there is a need to identify the proper protein solubilization 
buffer and protocol. The choice of lysis buffer and experimental procedure is critical for the 
solubilisation of the sperm proteins (278). In order to identify the best protocol for protein 
extraction of human sperm, eight different procedures were evaluated (Annex IV A) prior to 
final sample protein extraction. The procedure that presented the best results (Annex IV B) 
was then employed for protein extraction of the reserved pellets.  
 
7. Colorimetric detection and quantitation of total protein 
To quantify sample’s protein content after extraction a BCA Protein Assay Kit (Thermo 
Fisher Scientific) was implemented according to the manufacturer’s instructions. This kit 
was a detergent-compatible formulation based on bicinchoninic acid (BCA) for the 
colorimetric detection and quantitation of total cellular protein content. The quantification is 
based on a purple-coloured reaction, due to the chelation of two molecules of BCA with one 
cuprous ion, with strong absorbance at 562nm. The absorbance values have a linear 
correlation with increasing protein concentrations. Sperm protein concentrations were 
determined based on a standard curve of known concentrations of bovine serum albumin 
(BSA, Thermo Fisher Scientific).  
 
8. Sperm oxidative stress analysis  
Oxidative stress can be assessed by the cellular protein carbonyl content, a marker 
for protein oxidation, the measurement of aldehyde products such as 4-hydroxynonenal (4-
HNE), an indicator of lipid peroxidation, and by the quantification of 3-nitrotyrosine (3-NT), 
an indicator of superoxide-dependent peroxynitrite formation. The content of protein 
carbonyl groups, 4-HNE and 3-NT in spermatozoa from the different experimental groups 
was evaluated using the Slot-Blot technique and specific antibodies.  
 
 
8.1 Lipid peroxidation and protein nitration procedure:  
i. Protein samples were diluted to a final concentration of 0,03 µg/µl; 
ii. PVDF membranes were activated in methanol for 30 seconds and purified water for 
5 min; 
iii. 100 µl of each sample was added to the Slot-Blot wells;  
iv. Samples were towed from the wells with a vacuum pump until wells were dry; 
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v. The resulting membranes were blocked for 90 min in 5% low fat milk powder 
dissolved in TBS (Merck) with 0.05% Tween 20 (Sigma); 
vi. Membranes were then incubated overnight at 4ºC with a goat anti-4-HNE antibody 
(1:5000, AB5605, Merck) for lipid peroxidation and with rabbit nitro-tyrosine antibody 
(1:5000, 9691, Cell Signaling Tecnology, Massachusetts, USA) for protein nitration; 
vii. Membranes were incubated with secondary antibodies at for 1h at RT, using rabbit 
anti-goat IgG-AP (for 4-HNE) (1:5000, A4187, Sigma) or goat anti-rabbit IgG-AP (for 
3-NT) (1:5000, sc-2007, Santa Cruz Biotechnology, Heidelberg, Germany); 
viii. Membranes were then reacted with ECFTM substrate (GE Healthcare, 
Buckinghamshire, UK) and read in a Bio-Rad Gel Doc XR+ (Bio-Rad, Hemel 
Hempstead, UK); 
ix. Each band density was quantified using Quantity One Software Version 4.6.9 (Bio-
Rad). 
 
 
8.2 Carbonyl groups analysis procedure: 
i. Protein samples were diluted to a final concentration of 0,05 µg/µl; 
ii. Protein samples were derivatized using 2,4-dinitrophenylhydrazine (DNPH) to 
obtain 2,4- dinitrophenyl (DNP) (245).  
iii. PVDF membranes were activated in methanol for 30 seconds and purified water for 
5 min; 
iv. 100 µl of each sample was added to the Slot-Blot wells;  
v. Samples were towed from the wells with a vacuum pump until wells were dry; 
vi. The resulting membranes were blocked for 90 min in 5% low fat milk powder 
dissolved in TBS-T with 0.05% Tween 20; 
vii. The resulting PVDF membranes were incubated overnight at 4ºC with a rabbit anti-
DNP (1:5000, D9656, Sigma); 
viii. Membranes were incubated with a secondary antibody for 1h at RT, using a goat 
anti-rabbit IgG-AP (3-NT and DNP) (1:5000, sc-2007, Santa Cruz Biotechnology); 
x. Membranes were then reacted with ECFTM substrate (GE Healthcare) and read in 
a Bio-Rad Gel Doc XR+ (Bio-Rad); 
xi. Each band density was quantified using Quantity One Software Version 4.6.9 (Bio-
Rad). 
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9. Proton Nuclear Magnetic Resonance (1H-NMR)  
The extracellular metabolites from each sample after the incubation period were 
acquired by 1H-NMR. Sodium fumarate at a final concentration of 1 mM was used as an 
internal reference (6.50 ppm) to quantify the following metabolites (multiplet, ppm): H1-α 
glucose (doublet, 5.22); choline (singlet, 3.18); pyruvate (singlet, 2.38); acetate (singlet, 1.9) 
and lactate (doublet, 1.33 ppm). The relative areas of 1H-NMR resonances were quantified 
using the curve-fitting routine supplied with the NUTSpro NMR spectral analysis program 
(Acorn NMR, Livermore, CA, USA). 
 
10. Statistical Analysis 
The statistical significance among the experimental groups was assessed by ANOVA, 
followed by Fisher’s LSD. Two-way ANOVA was performed for sperm morphology analysis 
and one-way ANOVA for all the remaining parameters evaluated. All data are shown as 
mean ± standard error of mean (SEM). Statistical analysis was performed using GraphPad 
Prism 6 (GraphPad Software Inc., San Diego, CA, USA). All P values < 0.05 were 
considered statistically significant. 
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II. NAC concentration  
 
NAC is primarily used as a mucolytic agent but is now being tested for the treatment 
of several health conditions due to its chemopreventive and antioxidant features. However, 
in vitro studies with this agent and human spermatozoa are scarce and there is little 
information regarding the optimal concentrations for its use in cell culture. As a result, the 
first step in the practical part of this project was to assess which concentration of NAC 
should be added to the SPM to better protect cells from etoposide without causing any extra 
damage. 
Four different concentrations of NAC (5, 1, 0.5 and 0.05 mM) were tested, alone and 
in combination with 25 µg of etoposide. To evaluate which one was the best, we tested 
these conditions in 3 different semen samples (n=3) and decided according to these 
preliminary results. After incubation, we proceeded with the semen analysis followed by 
DNA analysis for each sample.  The most relevant findings regarded the integrity of the 
spermatozoa. While evaluating the morphology of each sample after incubation (Figure VII-
7A), we discovered that high concentrations of NAC were responsible for a decrease in the 
percentage of normal spermatozoa. In fact, we could clearly see that samples exposed to 
high doses of NAC had several spermatozoa with granulated heads and presented several 
tails with no head (Figure VII-7B). 
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Figure VII-7. Alterations in spermatozoa morphology after exposure to increasing 
concentrations of NAC. (A) Percentage of normal spermatozoa with increasing doses of NAC; (B) 
Spermatozoa morphology after incubation with 5mM of NAC, total amplification 400X. Results are 
expressed as mean ± SEM (n=3 for each condition).   
A                                                                          B  
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A 5 mM NAC concentration disrupted spermatozoa integrity, directly interfering with 
the viability of these cells. Therefore, we set this concentration aside and evaluated the 
capability of NAC 1, 0.5 and 0.05 mM to protect sperm DNA integrity when cells were 
exposed to etoposide (25 µg). Samples exposed to etoposide revealed more than 30% of 
dark blue cells, with uncondensed DNA, after AB staining (Figure VII-8A). These 
percentages were similar in the samples treated with 1 and 0.5 mM of NAC. However, 
spermatozoa incubated with etoposide and 0.05 mM of NAC showed a 13% decrease in 
the percentage of immature chromatin condensation. After incubation with etoposide, 
samples had a 32.5% of normal spermatozoa with fragmented DNA (Figure VII-8B). The 
supplementation with 1 mM of NAC did not alter this percentage. However, when samples 
were supplemented with 0.5 and 0.05 mM of NAC, there was a decreased in these levels 
to values lower than 20%. 
 
  
Figure VII-8. Spermatozoa DNA integrity when exposed to etoposide and supplemented with 
decreasing concentrations of NAC. (A) AB positive spermatozoa, in percentage, after incubation; 
(B) TUNEL positive spermatozoa, in percentage, after incubation. Results are expressed as mean ± 
SEM (n=3 for each condition).   
 
These results led to the conclusion that a concentration of 0.05 mM of NAC would 
be the most appropriate to protect cells from etoposide, without interfering with spermatozoa 
integrity.   
  
A                                                              B  
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III. Semen Parameters Reference Values 
 
Semen sample parameters need to be compared with reference values to allow 
correct patient diagnosis and management. Furthermore, threshold values are likewise 
important for clinical trials and scientific investigations. The reference values given have 
been generated from the results of several studies of semen quality and men fertility (Table 
VII-2).  
 
 
Table VII-2. Lower reference limits (5th centiles and their 95% 
confidence intervals) for semen characteristics. 
Parameter Lower reference limit 
Semen volume (ml) 1.5 (1.4–1.7) 
Total sperm number (106 per ejaculate) 39 (33–46) 
Sperm concentration (106 per ml) 15 (12–16) 
Total motility (PR + NP, %) 40 (38–42) 
Progressive motility (PR, %) 32 (31–34) 
Vitality (live spermatozoa, %) 58 (55–63) 
Sperm morphology (normal forms, %) 4 (3.0–4.0) 
pH 7.2 
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IV. Spermatozoa protein extraction 
 
 To identify the best protocol for protein extraction of human spermatozoa we tested 
several procedures in 12 semen samples and quantified the amount of protein that each 
one was able to extract from one million spermatozoa. We then compared the results 
obtained for each procedure and selected the best one to use with samples, including in the 
present research. The procedures tested varied on the lysis buffer used, times of incubation 
and the presence or absence of a sonication step. Figure VII-9 represents the different 
approaches tested and the main distinct steps between them.  
 
Figure VII-9. Schematic representation of spermatozoa protein extraction protocols. A total of 
8 distinct approaches were tested. Spermatozoa were incubated in four different lysis buffer (1% 
Triton-X100, 1% Tergitol Type NP-40, Radio-Immunoprecipitation Assay buffer (RIPA) and 
Mammalian Protein Extraction Reagent (M-PER)) and then sonicated or not for 20 min at 4ºC.  
 
At the end of each procedure, samples were quantified using the BCA Protein Assay 
Kit according to the manufacturer’s instructions. To compare the different protocols we 
evaluated the quantity of protein extracted from one million spermatozoa (Figure VII-10). 
Although results were not significant, except for Triton X-100 with sonication and 
Mammalian Protein Extraction Reagent (M-PER, Thermo Scientific, Rockford, IL, USA) 
(p=0.001), the protocol with 1% Triton X-100 lysis buffer and 20 min sonication displayed 
the best outcomes. This condition had the highest mean of protein extracted (11 µg/µl) and 
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displayed more consistency of high results than all other protocols, without restricting 
amounts for latter protein use. 
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Figure VII-10. Protein extracted in µg/µl per one million spermatozoa after each procedure. 
Median of protein quantity extracted following each protocol. TS group displayed the higher median 
in comparison to the remaining procedures. Abbreviations: T, Triton X-100; TS, Triton X-100 with 
sonication; NP, NP-40; NPS, NP-40 with sonication; MPERS, MPER with sonication; RIPAS, RIPA 
with sonication. Statistical analysis was determined by one-way ANOVA, followed by Fisher’s LSD. 
Results are expressed as mean ± SEM (n = 12 for each condition). Significantly different results (p 
< 0.05) are indicated as: & - relative to TS group. 
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Spermatozoa protein extraction: Selected protocol 
 
1% Triton X-100 with sonication 
 
Procedure: 
1. Lysis buffer (1% Triton X-100, 2M Tris buffer (Sigma), supplemented with 1% 
protease inhibitor cocktail (PIC; Thermo Fisher Scientific, Waltham, MA, USA) and 
100 mM sodium orthovanadate (phosphatase inhibitor; Sigma) was added to the 
sperm pellet; 
2. Incubated for 1 h at 4°C, while gently shaken;  
3. Sonicated for 20 min at 4°C; 
4. Centrifuged at 14000 xg for 20 min at RT; 
5. The resulting pellet was discarded and supernatants were reserved at -20ºC.  
  
  
 
 
 
  
  
 
 
 
  
  
 
 
 
